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ABSTRACT
MODEL-BASED APPROACH FOR DIFFUSE GLIOMA CLASSIFICATION, GRADING,
AND PATIENT SURVIVAL PREDICTION
Zeina A. Shboul
Old Dominion University, 2020
Director: Dr. Khan M. Iftekharuddin

The work in this dissertation proposes model-based approaches for molecular mutations
classification of gliomas, grading based on radiomics features and genomics, and prediction of
diffuse gliomas clinical outcome in overall patient survival. Diffuse gliomas are types of Central
Nervous System (CNS) brain tumors that account for 25.5% of primary brain and CNS tumors and
originate from the supportive glial cells. In the 2016 World Health Organization’s (WHO) criteria
for CNS brain tumor, a major reclassification of the diffuse gliomas is presented based on gliomas
molecular mutations and the growth behavior. Currently, the status of molecular mutations is
determined by obtaining viable regions of tumor tissue samples. However, an increasing need to
non-invasively analyze the clinical outcome of tumors requires careful modeling and co-analysis
of radiomics (i.e., imaging features) and genomics (molecular and proteomics features). The
variances in diffuse Lower-grade gliomas (LGG), which are demonstrated by their heterogeneity,
can be exemplified by radiographic imaging features (i.e., radiomics). Therefore, radiomics may
be suggested as a crucial non-invasive marker in the tumor diagnosis and prognosis. Consequently,
we examine radiomics extracted from the multi-resolution fractal representations of the tumor in
classifying the molecular mutations of diffuse LGG non-invasively. The proposed radiomics in the
decision-tree-based ensemble machine learning molecular prediction model confirm the efficacy
of these fractal features in glioma prediction. Furthermore, this dissertation proposes a novel noninvasive statistical model to classify and predict LGG molecular mutations based on radiomics and
count-based genomics data. The performance results of the proposed statistical model indicate that
fusing radiomics to count-based genomics improves the performance of mutations prediction.
Furthermore, the radiomics-based glioblastoma survival prediction framework is proposed in this
work. The survival prediction framework includes two survival prediction pipelines that combine
different feature selection and regression approaches. The framework is evaluated using two recent
widely used benchmark datasets from Brain Tumor Segmentation (BraTS) challenges in 2017 and

2018. The first survival prediction pipeline offered the best overall performance in the 2017
Challenge, and the second survival prediction pipeline offered the best performance using the
validation dataset. In summary, in this work, we develop non-invasive computational and
statistical models based on radiomics and genomics to investigate overall survival, tumor
progression, and the molecular classification in diffuse gliomas. The methods discussed in our
study are important steps towards a non-invasive approach to diffuse brain tumor classification,
grading, and patient survival prediction that may be recommended prior to invasive tissue
sampling in a clinical setting.
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CHAPTER 1

INTRODUCTION

Diffuse, or infiltrative, gliomas are types of Central Nervous System (CNS) brain tumors
that account for 25.5% of primary brain and CNS tumors and 80% of malignant tumors [1].
Gliomas are considered the most malignant primary brain and CNS tumors. Gliomas originate
from the supportive glial cells that consist of three major types: oligodendrocytes, astrocytes, and
ependymal cells [2]. Glial cells and neurons are the two major types of cells in the neural tissues.
However, only glial cells can undergo cell division, and if the process of cell division is not
carefully controlled and happens too fast, glioma forms and grows [3]. The broad range of glial
cells causes different forms of gliomas: astrocytomas, oligodendrogliomas, and mixed gliomas
such as oligoastrocytomas [4]. The 2007 World Health Organization (WHO) classification of
gliomas was based on microscopic similarities with different cells of origin and their levels of
malignancy. For example, Gliomas’ main types were classified based on their malignancy into
grades II, III, and IV [5, 6]. The WHO grade II gliomas (low-grade gliomas) are generally
infiltrating and have low mitotic activity (cell division and proliferation) and tend to progress to
higher grades. The WHO grade III gliomas (high-grade gliomas) have a rapid mitotic activity and
infiltrative capacity. The WHO grade IV gliomas (high-grade gliomas) have high mitotic activity,
appear with necrosis, and usually are accompanied by a rapid progression and fatal outcome [5,
7].
Recently, studies have revealed the importance of the genetic elements in tumor formation
and growth; such understanding may lead to greater diagnostic accuracy, as well as improved
patient management and more accurate determination of prognosis and treatment response [8-11].
Major revision of diffuse gliomas of the 2007 CNS WHO classification have been introduced in
the 2016 CNS WHO classification [12], which is established based on a combined phenotypic and
genotypic classification, and the generation of “integrated” diagnoses. An updated classification
of the diffuse lower-grade gliomas (LGG) is presented in the 2016 WHO Classification of Tumors
of the CNS [12]. The new classification of the diffuse LGG (WHO Grade II and III gliomas)
depends on the genetic driver mutations (IDH mutations, 1p/19q codeletion, and ATRX mutations),
and their histological type (astrocytoma and oligodendroglioma) as illustrated in Figure 1. Note
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that oligoastrocytomas are considered as not otherwise specified (NOS) categories unless there is
no diagnostic molecular testing. This new classification correlates with patients’ treatment and
survival. The histological types have different clinical behavior; oligodendroglioma tumors are
associated with longer survival when compared to astrocytoma [13].

Figure 1: The 2016 WHO Classification of the diffuse gliomas based on their histology
and genetic mutations [12].

Isocitrate Dehydrogenase mutations, IDH1, and IDH2 have been found in gliomas [14-17].
Classifying gliomas based on their molecular profiling of IDH status (mutated vs. wildtype) creates
clinically distinct groups. IDH wild-type gliomas behave aggressively when compared with the
IDH mutant gliomas. As a result, patients with IDH mutant gliomas tend to have a better prognosis
[18]. A 1p/19q codeletion is considered a molecular marker of oligodendroglioma and is associated
with IDH mutation [19]. This genetic alteration happens when the short arm of chromosome 1
(1p), and the long arm of chromosome 19 (19q) are deleted. The existence of 1p/19q codeletion in
diffuse LGG is associated with improved survival and with IDH mutations [16].
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Using IDH mutation and 1p/19q codeletion, the diffuse LGG is classified into three groups
[20]: 1p/19q codeletion with IDH mutant, 1p/19q non-codeletion with IDH mutant, and 1p/19q
non-codeletion with IDH wild-type. ATRX is a somatic mutation in the Alpha-Thalassemia/mental
Retardation syndrome, X-linked. This somatic mutation is reported in GBM [21]. This type of
mutation frequently occurs in diffuse Astrocytoma and is associated with a significantly better
prognosis [22, 23]. In addition, ATRX mutation has often occurred with IDH mutations and almost
mutually exclusive with 1p/19q codeletion. Another molecular alteration that has a high prevalence
of LGG is O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation [24].
Patients with a methylated MGMT promoter are associated with better overall survival [25, 26]. It
has a better impact on overall survival if MGMT methylation is combined with IDH mutation and
1p/19q codeletion [25]. Diffuse LGG is known for its heterogeneous characteristic that reveals
variances in tumor biology. This heterogeneity can be seen through the histological types:
astrocytoma, oligoastrocytoma, and oligodendroglioma [5, 12]. The heterogeneity can be
characterized by magnetic resonance imaging (MRI) features [27-29], which suggests using MRI
features as a non-invasive marker in tumor grading and classification [30-32].
Another diffuse infiltrative glioma is Glioblastoma multiforme (GBM). GBM accounts for
14.6% of primary brain and CNS tumors, 48.3% of primary malignant brain tumors, and 57.3%
of gliomas [1]. GBM is staged as a WHO grade IV tumor [5] and arises from astrocytes glial cells.
The extensive infiltrative growth pattern of Glioblastoma makes the curative treatment impossible
and, hence, reduces the median survival rate to 15 - 16 months [33]. The naming “multiforme” in
GBM emphasizes the heterogeneous nature of this type of glioma. The updated 2016 WHO
classification of GBM is divided into GBM with IDH-wildtype, GBM with IDH-mutant, and NOS
GBM, which is reserved for those tumors for which full IDH evaluation cannot be performed [34].
GBM IDH-wildtype accounts for ~90% of GBM, most frequently corresponds to primary (de
novo) glioblastoma, and predominates in patients with a mean age of 61 years old. The median
overall survival of GBM IDH-wildtype patients who are treated with surgery and radiotherapy is
9.9 months and 15 months when treated with surgery and radio/chemotherapy. GBM IDH-mutant
accounts for 10% and corresponds to secondary GBM (i.e. with a history of prior lower grade
diffuse gliomas) in patients with a mean age of 48 years. The median overall survival of GBM
IDH-mutant patients is 24 months when treated with surgery and radiotherapy and 31 months when
treated with surgery and radio/chemotherapy. Glioblastomas heterogeneity may show significant
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intertumoral (tumor by tumor) and intra-tumoral (within a tumor) heterogeneity. The tumor
heterogeneity impacts the clinical outcome and overall survival [35, 36]. Thus, analyzing this
heterogeneity is important for associating tumor phenotype with prognostic and predictive
purposes [37].

1.1 DISSERTATION GOALS AND PROBLEM STATEMENT

In current radiology practice, radiomics have a critical role in disease diagnosis,
monitoring, treatment planning, and personalized medicine [38, 39]. Radiomics acquisition is
extracted from various radiological imaging modalities of the disease’s region of interest, which
translates the radiographical images into useful data. Fusing crucial radiomics with clinical data in
the proper machine/deep learning model may help to obtain a more comprehensive disease
diagnosis and reliable early assessment of prognosis and treatment planning, and more
personalized or precise medicine [40, 41]. Improving personalized treatment and precision
medicine requires an accurate survival prediction, a fast and precise tumor detection, improved
molecular grading and classification, and a detailed therapeutic response assessment of oncologic
patients. Improvements in personalized medicine have succeeded as a consequence of advances in
biologic and genomic technologies that rely on invasive methods of tissue sampling [42-44].
However, tissue sampling may also be associated with high cost, morbidity, and even mortality
[45]. Also, in heterogeneous tumors such as glioblastomas, tissue sampling may not reflect the
entire heterogeneity of the tumor. Consequently, developing alternative methods and noninvasively analyzing patients’ survival-time prediction and classifying diffuse gliomas into
subtypes using imaging features and machine learning techniques have emerged as vital and
promising areas of research.
This study introduces a non-invasive automatic gliomas molecular classification and
grading prediction based on radiomics extracted from conventional magnetic resonance imaging
and clinical data. Also, we develop a glioma grading model based on genomics count-based data
and radiomics utilizing statistical modeling. Additionally, we introduce a radiomics guided noninvasive gliomas clinical outcome of overall survival in patients with glioblastoma.
The first goal of this dissertation addresses a non-invasive analysis of low-grade glioma
grading and classification using radiomics features based on the 2016 WHO Classification of
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Tumors of the CNS [12]. The new classification of the diffuse LGG depends on the genetic driver
mutations (MGMT methylation, IDH mutation, 1p/19q codeletion, ATRX mutation, TERT
mutation, and TP53 mutation). Because diffuse LGG is known for its heterogeneous characteristic,
MRI features can be used to characterize this heterogeneity. The second goal of this dissertation is
to propose a statistical radiogenomics model that utilizes both RNA sequencing (RNAseq) read
counts data and radiomics for glioma molecular grading and prediction. The Negative Binomial
(NB) distribution is fitted to RNAseq read counts to preserve the count-based nature of these data,
and a log-linear regression modeling is fitted to the estimated mean of the NB distribution and
linked with radiomics. Thus, a complete characterization radiogenomics prediction model is
presented. The third goal of this dissertation is to obtain a radiomics-guided machine learning
model for survival regression and prediction. In this work, we propose two representative survival
prediction pipelines that combine different feature selection and regression approaches. The
framework is evaluated using two widely used benchmark datasets from Brain Tumor
Segmentation (BraTS) global challenges in 2017 and 2018.
In general, alternative non-invasive radiomics-based machine learning models are critical
in the body of research to analyze and predict glioma clinical outcomes prior to invasive tissue
sampling. Although invasive tissue sampling is effective, non-invasive radiomics-based models
may be preferred if these models offer competitive performance. The efficacy of the radiomicsbased models proposed in this work indicates the potential of correlating radiomics (computed
imaging features) with glioma molecular mutations types and overall survival. These models also
identify candidates that may be considered potential predictive biomarkers of glioma molecular
classification and overall survival. Furthermore, the recent interest in associating genomic
phenotypes and radiomics has shifted the research towards utilizing both types of data in a single
computational modeling framework to analyze different aspects of glioma clinical outcomes.

1.2 CONTRIBUTIONS

The main contributions of this dissertation are discussed as follows:
1.

Effective non-invasive analysis of diffuse low-grade gliomas grading and classification using
radiomics features based on the 2016 WHO Classification of Tumors of the CNS
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The 2016 WHO classification of diffuse LGGs heavily weighs molecular mutations
classifying primary brain tumors with particular importance assigned to IDH mutation, 1p/19q
codeletion, ATRX mutation, TERT mutations, and MGMT methylation. The second goal proposes
and develops an imaging feature-based, computational machine learning model for diffuse LGGs
classification and grading. Our model on diffuse LGG is largely able to predict the presence of the
important molecular mutations as identified by WHO based on MR imaging features. Therefore,
prediction of tumor aggressiveness (based on molecular mutations) may be achieved through noninvasive imaging features as an adjunct to traditional visual morphologic diagnosis and invasive
tissue sampling. The proposed model addresses possible overfitting, model instability, and the
efficacy of fractal and multifractal textures on the performance of the proposed molecular mutation
prediction models. To the best of our knowledge, this is the first study that addresses the potency
of fractal and multi-resolution fractal features in molecular mutations prediction. The experimental
demonstrations of the proposed molecular mutation prediction show promise when compared to
different methods and models in the literature. The proposed methods are important steps towards
non-invasive imaging classification of diffuse LGG based on molecular mutations prior to invasive
tissue sampling.
2. A novel RNA Sequencing and Radiomics statistical fusion model (radiogenomics-Negative
Binomial) for Glioma Grading and Prediction
In current radiology practice, radiomics plays a key role in disease diagnosis, monitoring,
treatment planning, and grading [38, 39]. Radiomics is extracted from various radiological images
of a targeted area of the disease. Fusing the important radiomics and genomics information in the
computational machine learning (ML) model may help in achieving a comprehensive disease
diagnosis, prognosis, and treatment plan. Consequently, such fusion may yield a personalized or
precision medicine model [40, 41]. The rise of radiogenomics introduces more comprehensive and
better profiling of personalized medicine for patients [27, 46-48]. Thus, associating between the
radiomics phenotypes and underlying disease molecular mutations enhances clinical oncology care
[49-51]. Different studies evaluate the association between glioma molecular subtypes and
radiomics (e.g., tumor shape and size) [52-54] or between different forms of genomics (e.g., RNA
sequencing (RNAseq) gene expression, protein expression, copy number, molecular mutations, or
DNA methylation) and glioma subtypes [55-57]. These associations help to pave the way for ML-
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based classification of glioma molecular subtypes using radiomics [58-60], genomics [57, 61], or
both [62-64].
Conventional ML models do not adequately model the count-based nature of the RNAsequence data as these models are usually designed to work with data that has a normal
distribution. In order to alleviate the lack of appropriate ML models, researchers propose to
transform the RNAseq read-count data to approximate a normal distribution. The transformation
to normal distribution allows the use of existing methods such as the nearest shrinkage method
[65, 66] and Random Forest for classification. However, such transformation still removes the
count-based nature of the RNAseq read counts data and, hence, lacks the ability to fully preserve
the strong mean-variance relationship that is otherwise useful for glioma classification and
prediction [67, 68]. In order to appropriately model the RNAseq read-count data, Negative
Binomial (NB) and Poisson distributions are commonly used [69]. Poisson distribution is a single
parameter distribution with its mean equals to its variance, which makes Poisson distribution rather
restrictive. On the other hand, NB is similar to a Poisson distribution with an additional parameter
called “dispersion” that allows the NB distribution to modify its variance without affecting the
mean. On the other hand, existing works suggest the efficacy of using both genomics and radiomics
data in the classification and prediction of different disease modality [70-73].
Consequently, this work proposes fusing RNAseq read counts data with radiomics in NB
distribution to classify and predict glioma molecular mutations. Moreover, log-linear regression
modeling is fitted to the estimated mean of the NB distribution and is linked with radiomics. We
introduce this step to fuse the continuous radiomics data with the RNAseq count-based data
without the need to transform RNAseq data into a normal distribution.
Finally, we investigate the effect of using different numbers of differentially expressed
genes from the count-based data as well as the gender factor by developing a gender-specific
radiogenomics-NB model. Moreover, we compare our radiogenomics-NB model performance
with that of different genomics and radiogenomics state-of-the-art methods in the literature.
3.

An efficient non-invasive machine learning for radiomics-based Glioblastoma survival
regression and classification
Different studies [74-76] have discussed different methods of predicting the survivability

of patients with brain tumors. Pope et al. [74] use different subtype tumor volumes, the extent of
resection, location, size, and other imaging features in order to assess the potential of these features
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in predicting survival probabilities using the Kaplan-Meier method. Gutman et al. [75] use a
comprehensive visual features set known as Visually AcceSAble Rembrandt Images (VASARI)
in their study with glioblastoma patients. The authors have assessed the relationship between
VASARI features and patients’ survival using multivariate Cox regression models and correlated
these features with genetic alterations and molecular subtypes by using the Fisher exact test. Aerts
et al. [76] predict survival using a multivariate Cox proportional hazards regression model by
quantifying a large number of radiomics image features including shape and texture in computed
tomography images of lung and head-and-neck cancer patients. Several of the survival prediction
studies have been utilizing regression survival [77, 78] models such as the proportional hazard
method. Lately, machine learning is replacing these proportional hazard methods to predict
survival [79-81]. In this work, we utilize Random Forest and XGBoost in the survival regression
and classification model. A feature-guided non-invasive machine learning approach is expected to
benefit from known imaging features that are already proven effective to guide the efficacy of the
proposed pipelines. Consequently, this work proposes a fully automated overall survival regression
classification using imaging features extracted from the tumor volume of the raw structural MRI
and three different texture characterizations of the tumor region. Finally, the framework is
evaluated using two recent widely used benchmark datasets and global challenges in Brain Tumor
Segmentation (BraTS) global challenges in 2017 and 2018, respectively. The overall contributions
of this dissertation are summarized in Table 1.
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Table 1. Summary of the research findings related to the proposed methods.
Chapter
3

Dissertation goals

Proposed Methods

Prediction and evaluation of

A XGBoost classification and

Non-invasive

tumor aggressiveness using

prediction model using fractal and

prediction model and efficacy

molecular mutations through

non-fractal features as input and

validation of fractal features for

non-invasive

molecular mutation information as

glioma

the target output.

using traditional MRI data based

fractal

multi-resolution

and
fractal

Novel Contributions
molecular

molecular

prediction

imaging features as adjunct

on

marker.

classification of LGG of the

the

latest

2016

WHO

CNS.
4

Glioma

grading

and

using

joint

Binomial

model

statistical modeling of RNA

radiomics

(volumetric

imaging

model (radiogenomics-Negative

sequencing and radiomics.

features) with RNAseq (genes) for

Binomial) for Glioma grading

glioma grading and prediction.

and prediction, where a log-

Negative Binomial distribution is

linear regression model links

proposed to fit RNAseq counts

between the estimated NB mean

data.

and radiomics.

Glioma survival regression

Two ML models for survival

A novel framework for fully

and classification using novel

prediction are developed:

automated

prediction

5

radiomics-based

machine

learning (ML) methods

A

radiogenomics-Negative

a.

A

that

three-step

selection

along

fuses

feature
with

RF

regression classifier.
b.

A

Radiomics

statistical

radiomics-based

Glioblastoma
prediction
competitive

fusion

survival
that
results

provides
when

feature

compared with the state-of-the-

selection along with XGBoost

art methods in BraTS 2017 and

for classification step followed

BraTS 2018 challenges and

by a Cox regression along with

ranked first in BraTS 2017

three

recursive

A novel RNA Sequencing and

risk-based

regression

Challenge.

models.

1.3 ORGANIZATION OF THE DISSERTATION

The rest of the dissertation is organized as follows. Chapter 2 provides a background review
on Gliomas’ survival and molecular mutation analysis and prediction using different sources of
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features. Additionally, this chapter provides a background review on utilizing RNAseq read counts
data in molecular mutations in diffuse LGG. Chapter 3 studies different molecular prediction
models utilizing fractal and multi-resolution fractal texture features and other MR imaging features.
The molecular models include the IDH, 1p/19q codeletion, MGMT, ATRX, and TERT prediction.
In Chapter 4 we propose an RNA-radiomics (henceforth referred to as radiogenomics) -NB model
for glioma grading and prediction. Our radiogenomics-NB model is developed based on
differentially expressed RNAseq and selected radiomics features. Chapter 5 proposes a fully
automated glioblastoma survival prediction framework based on MR imaging features. The survival
prediction step includes two representative survival prediction pipelines that combine different
feature selection and regression approaches. Chapter 6 provides the dissertation concluding remarks
and future research.
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CHAPTER 2

BACKGROUND REVIEW

This chapter discusses the relevant previous work on glioma survival analysis and
prediction, molecular mutations prediction in diffuse LGG based on MRI features, and molecular
mutations classification based on RNAseq read counts data and MRI features.

2.1 GLIOBLASTOMA SURVIVAL PREDICTION

The World Health Organization (WHO) identifies Glioblastoma as a highly diffusive
aggressive grade IV glioma, which is known for the presence of anaplastic glial cells, high mitotic
activity, and dense cellularity, as well as an increase in microvascular proliferation [5, 82, 83]. The
highly infiltrative growth pattern of Glioblastoma makes curative care difficult with a median
survival time of less than 2-years [84]. Recently, research interests have been focused on replacing
invasive methods of patients’ diagnosis and prognosis outcome with non-invasive methods [31,
32, 49]. Glioblastoma heterogeneity and its implication on patients’ clinical outcomes [29, 36, 85]
can be explored through radiology images such as MRI [31, 86, 87]. Thus, accurate detection and
segmentation of different abnormal tumor tissues are essential in planning treatment therapy,
diagnosis, grading, and survival prediction.
Few works [74-76] have proposed different methods for assessing and predicting the
survivability of patients with brain tumors using clinical data and imaging features. Pope et al. [74]
evaluate and analyze the capability of different subtype tumor volumes, the extent of resection,
location, size, and other imaging features in predicting the survivability of patients with grade III
and grade IV GBM. The study reveals that patients’ age at diagnosis and Karnofsky Performance
Status (KPS) shows a significant prognostic for both GBM grades. Additionally, a univariate Cox
analysis shows that the tumor imaging features of non-contrast enhancing tumor, edema, satellites,
and multifocality are statistically significant prognostic indicators in patients with GBM. Gutman
et al. [75] conduct a comprehensive analysis of the visual features set known as Visually
AcceSAble Rembrandt Images (VASARI) to study their association with GBM genetic mutations,
molecular subtypes, and patient survival rate. The authors utilized four cardinal VASARI MR
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imaging features along with a single measure of lesion size. Their analysis reveals that the volume
of the contrast-enhancing tumor and the longest axis length of the GBM are statically associated
with poor survival. The analysis also reveals that VASARI imaging features are associated with
genetic alterations and molecular subtypes. However, the authors only address the visual features
set and focus on the semi-quantitative measurements of the different tumor compartments and have
not addressed other texture features. Aerts et al. [76] study the prognostic value of a large number
of radiomics image features in computed tomography images of lung and head-and-neck cancer
patients. These features include tumor image intensity, shape, texture, and multiscale wavelet. The
authors perform a Kaplan-Meier survival analysis to study such an association. Additionally, the
authors select the most important radiomics feature from each feature set, then utilize these four
features in a multivariate Cox proportional hazards regression model for prediction of survival.
Nicolasjilwan et al. [88] utilize clinical data, VASARI features, and genomics (represented by
copy number variations) of GBM patients and combine these features into a stepwise multivariate
Cox model for prediction of overall survival time. Prasanna et al. [89] extract radiomics texture
features that characterize three tumor regions: enhanced tumor, peritumoral brain zone, and
necrosis from MR images. These features are assessed for overall survival prediction. Itakura et
al. [49] utilize quantitative MRI features that describe tumor histogram statistics, texture, edge
sharpness, compactness, and roughness. Then the authors cluster the features into three MRI
phenotypic imaging subtypes: pre-multifocal, spherical, and rim-enhancing tumor. The three
distinct subtypes are then correlated with overall survival and associated with molecular pathways.
The prevailing survival analysis and prediction studies have employed statistical survival
regression techniques such as Kaplan-Meier and proportional hazard methods [76-78, 88].
Statistical survival analysis methods such as Kaplan-Meier and Cox regression analysis have
difficulty capturing the complex relationship between the covariates and the outcome and suffer
from cumulative incidence overestimation [90]. Recently, research has shifted towards replacing
these statistical methods with improved machine learning methods because of the latter’s
computational power, accuracy, and ability to employ a large number of different types of features.
In this study, we hypothesize that radiomics imaging features along with the proposed
machine learning techniques may offer superior efficacy in selecting important radiomics imaging
features and predicting overall survival. In this study, we propose two fully automated survival
prediction frameworks for patients with glioblastoma: overall survival regression using Random
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Forest model [91] and overall survival classification and regression using Extreme Gradient
Boosting (XGBoost) [92]. Radiomics imaging features are obtained from 1) raw structural MRI
data, 2) Texton [93] characterization of the raw MRI, 3) and fractal and multi-resolution fractal
representations of the raw MRI. Fractal and multi-resolution fractal have shown their efficacy in
brain tumor segmentation in prior studies [94-98]. The proposed framework is evaluated using two
recent widely used benchmark datasets from Brain Tumor Segmentation (BraTS) global
challenges in 2017 and 2018, respectively. Our results suggest that the proposed framework
achieves better overall survival prediction performance compared to the state-of-the-art methods.

2.2 MOLECULAR MUTATIONS IN DIFFUSE LOW-GRADE GLIOMAS

The 2016 WHO classification of diffuse LGGs is based on molecular profiling to IDH
mutation, 1p/19q codeletion, ATRX mutation, TERT mutations, and MGMT methylation. Such
profiling requires invasive tumor tissue sampling However, non-invasive analysis of tumor
aggressiveness using Imaging features is emerging to replace the invasive tissue sampling. An
MGMT methylation prediction study by Kanas et al. [59] for patients with GBM reports the size
of the tumor with respect to necrosis as one of the significant features. A GBM study conducted
by Kanas et al.[59] proposes an MGMT prediction model using volumetric, morphological, and
locational MR imaging features, respectively. The authors in [59] report the size of the tumor with
respect to necrosis as one of the significant features. However, the entire process of the prediction
model is not fully automated. Another study by Han et al. [99] where the authors use a bidirectional convolutional recurrent neural network to predict MGMT methylation status. One
major drawback of their study is that their model mainly utilizes imaging features that cannot be
correlated with tumor biology. In an IDH prediction model by Yu et al. [100] on 110 patients with
Grade II glioma, the authors use 110 imaging features and SVM to classify IDH status with Grade
II glioma patients. However, the performance would reflect higher reliability of the performance
of the IDH status prediction model if the dataset they use was more diverse with patients from
Grade II and Grade III gliomas. A different study by Ding et al. [101] on 76 LGG patients utilizes
MR imaging features along with MR spectroscopic data to predict IDH mutations using a binary
logistic regression model. The authors achieved the best performance when utilizing MR
spectroscopic data. A study by Akkus et al.[102] with LGG patients proposes 1p/19q codeletion
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prediction using a convolutional neural network (CNN). In their study, the authors represent each
patient’s MRI with only 3 MRI slices. The authors in Akkus et al. [102] do not consider the global
information of the tumor since their dataset uses only 3 slices of the MRI sequence of each patient
as input, not the whole volume of the tumor. A different recent study by van der Voort et al. [103]
utilizes MR imaging features along with patients’ age and sex using an SVM classifier to predict
1p/19q codeletion in LGG patients. The authors use 284 LGG patients for training and another 129
LGG patients for testing. Their analysis reveals that the cranial/caudal location of the tumor is one
of the most important features in predicting 1p/19q codeletion. Recently, Wang et al. [104] explore
survival prediction and TERT mutations in 39 LGG (30 WT, and 9 Mutant). The authors propose
a TERT prediction model using 24 imaging features selected using Principle Component Analysis
(PCA) and classified using the Partial Least Squares (PLS). One major concern about their study
is that the number of selected features (24 imaging features) is relatively high when compared to
the dataset size (39 patients), which would increase the possibility of overfitting problems. In this
work, we propose a fully automated computation prediction method of LGG molecular mutations
utilizing radiomics imaging features. In our study, we utilize a more diverse dataset using Grade
II and III, where significant and imaging features 1) are extracted from conventional MR imaging
volumes that are clinically available and 2) are associated with overall survival and tumor biology.
Additionally, we utilize fractal and multi-resolution fractal modeling. In this study, we hypothesize
that the fractal and multi-resolution fractal modeling may be related to the underlying structure of
molecular mutations. To the best of our knowledge, this is the first study that addresses the potency
of fractal and multi-resolution fractal features in molecular mutations prediction. Several studies
have shown the efficacy of fractal and multi-resolution fractal feature analysis for characterization,
segmentation, and classification of the complex abnormal brain tissues in MRI [94, 97, 105, 106].
The spatial intensity distribution which is a basic property that characterizes medical images (such
as MRI) have a degree of noise and randomness that allows the use of fractal and multi-resolution
fractal texture modeling efficiently. The multi-resolution fractal modeling captures the randomly
varying complex structure of the tumor texture on a different scale. Few studies have shown an
association between different types of imaging features such as the grey-level co-occurrence
matrix (GLCM) for texture, volume and area related features, and intensity-based features to the
tumor classification [107-110]. While GLCM features may capture the grey-level spatial variation
in an image, these deterministic features may not be effective in the analysis of the random surface
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structure variation of abnormal tumor tissues in MRI. Wavelet features, on the other hand, examine
the intensity variation of the tumor tissues in different image resolutions [111, 112]. In comparison,
the multi-resolution fractal modeling mathematically combines the capabilities of regular texture
analysis (e.g., GLCM) and multi-resolution analysis (e.g., wavelets) and, hence, may capture the
randomly varying complex structure of the tumor tissue texture at different scales. The spatial
intensity distributions of abnormal brain tissues in MRI have a degree of randomness that is
amenable to fractal and multi-resolution fractal texture modeling.

2.3 RNA SEQUENCING AND RADIOMICS

RNAseq is a new technology that employs next-generation sequencing technology (NGS).
RNAseq has developed as a novel technique to replace microarrays to measure gene expression.
In RNAseq, the gene expression level is quantified by counting the number of times the RNAseq
reads map (i.e. align) to one gene [113]. One of the major drawbacks of microarrays is background
noise. RNAseq starts with isolating RNA from the organism, then converts RNA fragments to
complementary DNA (cDNA), then prepares the sequencing library, and finally sequences the
cDNA using NGS platform. RNAseq is a very sensitive technique that provides high resolution
and a thorough understanding of the transcriptome and has revealed many novel gene structures.
RNAseq distribution requires an appropriate model that adapts and preserves the nature of
RNAseq read counts data, and such classification models that preserve the nature of RNAseq are
lacking in the traditional ML literature. The NB distribution is an appropriate choice to model such
discrete read counts data [69]. Even though traditional ML tools that are developed based on NB
are lacking, the choice of using NB distribution in differential gene expression and RNAseq
analysis has been adapted by different studies in literature such as in EdgeR [114-116], DESeq
[117], and NBPSeq [118]. In EdgeR [114-116], the authors estimate the NB dispersion parameter
using a quantile-adjusted conditional maximum likelihood estimator assuming a common
dispersion between the different genes and replicates. However, a common dispersion between the
different genes is generally not true. Therefore, reference [115] defines a weighted conditional loglikelihood as a combination of “individual” and weighted “common” likelihoods. The "common"
likelihood assumes all genes have a common dispersion value. The "individual" likelihood is
estimated by conditioning on the sum of counts of a gene for each class.
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An example of a count-based classifier that fits NB distribution is the Negative Binomial
Linear Discriminant Analysis (NBLDA). NBLDA is a well-known classifier that is developed by
fitting NB to RNAseq and the mean and dispersion parameter are estimated from the RNAseq data
[119]. In the NBLDA method, the dispersion parameter is estimated using the shrinkage estimator
that is proposed by Yu et al. [120]. A different type of classifier, known as VoomNSC, is developed
based on the transformed count data. VoomNSC is a combination of voom (an acronym for meanvariance modeling at the observational level) transformation [65] and the nearest shrunken
centroids classifier (NSC) [121]. Voom is designed as follows: first RNAseq read counts are
transformed as the log-counts per million (log CPM). Then, a relationship between the squareroot-standard-deviations and the mean of the log-count. Then, a precision weight (i.e., the inverse
of the variance) of each sample is estimated. The estimated weights and the log-counts are used to
build the NSC classifier. In NSC, a soft-thresholding shrinkage method is used to shrink each
weighted difference score between a particular gene centroid and the overall centroid toward zero.
Then, the updated weighted difference is used to update the weighted centroid for each remaining
gene (i.e. important genes). In the prediction step, the updated weighted centroids of the important
genes are used to predict the gene class.
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CHAPTER 3

PREDICTION OF MOLECULAR MUTATIONS IN DIFFUSE LOW-GRADE GLIOMAS
USING RADIOMICS

3.1 CHAPTER OVERVIEW

The 2016 WHO classification of CNS presents a major restructuring of diffuse gliomas.
The updated classification of diffuse gliomas group tumors based on the shared genetic driver
mutations, in addition to their growth pattern and behavior. Currently, the status of molecular
mutations such as IDH mutations, ATRX, mutation, TERT mutation, and 1p/19 codeletion is
determined by obtaining tissue samples that represent viable regions of the tumor with elevated
proliferation and neovascularization [122].
A shift into developing alternative methods to non-invasively classify diffuse LGG into its
different subtypes has inspired different research groups to employ the developing field of
radiomics and machine learning techniques. In this chapter, we address diffuse LGG grading and
classification prediction based on molecular mutations using imaging features that are extracted
from multimodality raw MRI sequences (T1, T1Gd, T2 FLAIR, and T2) of the anatomically
depicted tumor volume and texture representations of the tumor MRI sequences. The extracted
features describe the multi-resolution fractal features, texture features, volumetric, and area-based
characteristics. In this study, different molecular (IDH, 1p/19q codeletion, ATRX, and TERT), and
MGMT methylation prediction models are introduced. In addition, our study investigates the
efficacy of our novel texture features the fractal and multi-resolution fractal modeling on the
performance of the non-invasive prediction of molecular mutation in LGG.
Several studies have shown the efficacy of fractal and multi-resolution fractal feature
analysis for characterization, segmentation, and classification of complex abnormal brain tissues in
MRI [94, 97, 105, 106]. Consequently, in this study, we hypothesize that the fractal and multiresolution fractal modeling may relate to the underlying structure of molecular mutations. To the
best of our knowledge, this is the first study that addresses the potency of fractal and multiresolution fractal features in molecular mutations prediction.
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3.2 RADIOMIC-BASED LGG MOLECULAR MUTATION PREDICTION MODEL

3.2.1

DATASET

In this study, we use a total of 108 pre-operative LGG patients described in [123-125]. Four
sequences of the MRI are provided with the dataset: pre-contrast T1-weighted (T1), post-contrast
T1-weighted (T1Gd), T2-weighted (T2), and T2 Fluid Attenuated Inversion Recovery (FLAIR).
These scans are skull-stripped, re-sampled to 1 mm3 resolution, and co-registered to the T1

template. The dataset provides the segmented sub-regions of the LGG: Gadolinium enhanced tumor
(ET), the peritumoral edema (ED), and the necrosis along with non-contrast enhancing tumor
(NCR/NET). Molecular alterations (IDH mutation, 1p/19q codeletion, ATRX, and TERT mutation),
grade (II and III), and clinical data are downloaded from the Genomic Data Commons Data Portal
(https://portal.gdc.cancer.gov/). Clinical data are de-identified by the Health Insurance Portability
and Accountability Act of 1996 (HIPAA). The distribution of the data is as follows: (i) IDH
mutation: 85 Mutant (of which 27 cases are co-deleted) and 23 wildtype (WT), (ii) 1p/19q
codeletion: 27 codeletion and 81 non-codeletion, (iii) ATRX status: 43 Mutant and 65 WT, (iv)
TERT status: 46 Mutant and 62 WT, and (v) O6-methylguanine-DNA methyltransferase (MGMT)
promoter methylation: 91 methylated and 14 un-methylated. The patient age range of the at the time
of diagnosis is 20 – 75 years, and the median value is 46.5 years.
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Figure 2. An overview of the proposed LGG Molecular Mutation prediction Model.

3.2.2

METHODOLOGY

In this study, we introduce different molecular prediction models based on fractal and multiresolution fractal texture features and other MR imaging features. These molecular models include
the IDH, 1p/19q codeletion, MGMT, ATRX, and TERT prediction. A classic way to avoid
overfitting is to divide the dataset into training, validation, and testing datasets [126]. The dataset
is randomly partitioned into training (75% of the entire dataset = 81 cases) and testing (25% of the
entire dataset = 27 cases) subsets. A balanced distribution of the target molecular mutation is
ensured in the training and testing sets in each molecular prediction model. The features are
extracted from multimodality MRI sequences of the tumor volume in the training partition. Then,
a recursive feature selection is performed to select the number of features and is validated with
Leave-One-Out Cross-Validation (LOOCV). The selected features are then trained using an
Extreme Gradient Boosting (XGBoost) method along with LOOCV. Then, a prediction
performance is evaluated using the testing partition.
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Furthermore, we study the efficacy of fractal and multi-resolution fractal texture features
(e.g., piecewise-triangular prism surface area (PTPSA), multi-resolution fractional Brownian
motion (mBm), and Holder Exponent (HE)) extracted from tumor volumes on the performance of
the molecular mutation prediction models. Figure 2 shows the overall pipeline of the proposed
LGG-XGBoost prediction model for different molecular mutations in LGG.

3.2.3

FEATURE EXTRACTION

In this study, around 680 features are extracted to represent texture, volume, and area of the
tumor and its sub-regions (edema, enhanced tumor, and necrosis). These features include 41 texture
features [127] extracted from the tumor volume in raw MRI (T1Gd, T2, and FLAIR) sequences and
an additional three different texture characterizations of the tumor region. The three texture
characterizations are as follows:
•

fractal characterization using our PTPSA[96] modeling,

•

multi-resolution mBm[97] modeling,

•

and the characterization Holder Exponent (HE) [128, 129] modeling of the tumor region.
The computational algorithm of the PTPSA, mBm, and the HE is found in [96, 97, 130].

The 41 texture features are: global variance, skewness, kurtosis, energy, contrast, correlation,
homogeneity, variance, sum average, entropy, short-run emphasis, long-run emphasis, gray-level
non-uniformity, run-length non-uniformity, run percentage, low gray-level run emphasis, high
gray-level run emphasis, short-run low gray-level emphasis, short-run high gray-level emphasis,
long-run low gray-level emphasis, long-run high gray-level emphasis, gray-level variance, runlength variance, small zone emphasis, large zone emphasis, gray-level non-uniformity, zone-size
non-uniformity, zone percentage, low gray-level zone emphasis, high gray-level zone emphasis,
small zone low gray-level emphasis, small zone high gray-level emphasis, large zone low graylevel emphasis, large zone high gray-level emphasis, gray-level variance, zone-size variance,
coarseness, contrast, busyness, complexity, and strength.
Furthermore, six histogram-based statistics (mean, variance, skewness, kurtosis, energy,
and entropy) features are also extracted from the different tumor sub-regions (edema, enhanced
tumor, and necrosis), respectively.
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In addition, we extracted 12 volumetric features: the volume of the whole tumor, the volume
of the whole tumor with respect to the brain, the volume of sub-regions (edema, enhanced tumor,
and necrosis) divided by the whole tumor, the volume of sub-regions (edema, enhanced tumor, and
necrosis) divided by the brain, the volumes of the enhanced tumor and necrosis divided by the
edema, the summation of the volume of the edema and enhanced tumor, the volume of the edema
divided by the summation of the volume of enhanced tumor and necrosis, and the volume of the
necrosis divided by the summation of the volume of the edema and enhanced tumor. Finally, ninevolume properties (area, bounding box, centroid, perimeter, major axis length, minor axis length,
eccentricity, orientation, solidity, and extent) are extracted from the tumor volume and from three
viewpoints (x, y, and z-axes) of the tumor and its sub-regions (edema, enhanced tumor, and
necrosis).
Texture features are analyzed using MATLAB-based software developed by Vallières et
al.[127]. Fractal characterization, multi-resolution fractal characterization, HE characterization, and
volumetric features are analyzed using MATLAB-based in-house software.

3.2.4

MOLECULAR MUTATION PREDICTION MODEL AND FEATURE

SELECTION

The molecular mutation prediction model is performed on the training set using nested
LOOCV to avoid an optimistic performance estimate. Recursive feature selection is performed in
the inner loop to find the optimum features set. The LOO cross-validated performance of the
molecular mutation prediction model is estimated in the outer loop. The molecular mutation
prediction model is performed using the R statistical packages Caret and XGBoost (www.rproject.org).
Recursive feature selection (RFS) is implemented by first fitting a Random Forest (RF)
model to all features. Each feature is ranked by its importance, and the least important features are
removed from the current feature set. Then, this step is repeated recursively until the optimum
features set that has the best performance is reached. In our implementation of recursive feature
selection, the number of features in the features’ sets are 2, 3, 5, 7, 9, 11, 13, and 15 features. In
addition, the best performance is determined by maximizing the area under the receiver operating
characteristic (ROC) metric. The feature set that provides the combination of features that maximize
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the area under the ROC (AUC) is chosen for training in the prediction model. Using recursive
feature selection, the maximum number of selected features is fifteen so that the training samples
(eighty-one cases) is at least 5 times the number of features to reduce model overfitting.
In our study, XGBoost is utilized as a classification and prediction model using the
optimum features set as input and molecular mutation information as the target output. XGBoost
[131] is an advanced tree boosting supervised machine learning technique that is effective in
handling imbalanced datasets. XGBoost is widely used in classification and regression tasks. For
a given dataset 𝐷𝐷 with s samples and m features 𝐷𝐷 = {(𝑥𝑥𝑖𝑖 , 𝑦𝑦𝑖𝑖 )}(|𝐷𝐷| = 𝑠𝑠, 𝑥𝑥𝑖𝑖 ∈ ℝ𝑚𝑚 , 𝑦𝑦𝑖𝑖 ∈ ℝ ), a tree
ensemble model uses K additive functions to predict the output as follows,
𝑦𝑦�𝚤𝚤 = ∑𝐾𝐾
𝑘𝑘=1 𝑓𝑓𝑘𝑘 (𝑥𝑥𝑖𝑖 ) , 𝑓𝑓𝑘𝑘 ∈ 𝐹𝐹,

(1)

where 𝑥𝑥𝑖𝑖 is the feature/input vector, 𝑦𝑦𝑖𝑖 is the target/output variable, and 𝑓𝑓(𝑥𝑥) is a function in the

functional space 𝐹𝐹, and 𝐹𝐹 is a set of all possible classification and regression trees. One of the major
advantages of using XGBoost is that XGBoost provides L1 and L2 regularization. L1 regularization
handles sparsity, whereas L2 regularization reduces overfitting. In addition, we choose XGBoost
because it is known for handling an imbalanced dataset. A detailed mathematical derivation of the
XGBoost algorithm is found in Chen et al. [131]. The final molecular mutation prediction model
(that is used for the testing set) is obtained by fitting the optimum features set that maximizes
performance in the inner loop (over all the outer cross-validation loops). Note, if more than one
feature sets maximize inner loop performance, the common features between the features’ sets are
used. The prediction performance of the final molecular mutation model is tested using the paired
testing sets (partitions).
Finally, in order to study the efficacy of fractal and multi-resolution fractal texture features
used in this study (e.g., PTPSA, mBm, and Holder Exponent) on the performance of the proposed
prediction models as shown in Figure 2, we perform molecular prediction analyses with and
without these texture features, respectively. The entire process in Figure 2 is repeated n times

independently with n different training/testing set pairs. The n number of repetitions is a random
number between 10 and 15 that is generated for each model.
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3.2.5

MOLECULAR MODELS EVALUATION

The molecular models are validated using separate testing sets, and the prediction
performance (test performance) of the trained XGBoost model is estimated using AUC, sensitivity,
and specificity. After n times of independent repetitions, the ANOVA test is used to compare the
difference in the prediction performance between two models with and without the fractal and
multi-resolution fractal texture in the prediction models. In addition, ANOVA is used to analyze
the significant association between features and the different molecular mutations. The survival
groups that are formed using the significant features are compared using Kaplan-Meier curves and
the log-rank test. The hazard ratio of features is determined using the Cox proportional hazards
model and assessed using the likelihood-ratio test. Finally, the evaluation step for Survival is
conducted using R statistical packages.

3.3 EXPERIMENTAL RESULTS

Around 680 imaging features are extracted from multimodality MRI sequences. Recursive
feature selection is used to find the optimum number of significant features for each molecular
mutation prediction model. Our analyses of the different prediction models are repeated
independently n times with different training and testing pairs (partitions). Table 2 displays the
number of repetitions n, LOOCV performance, and the test performance of the different prediction
models when including/removing texture characterization of the fractal and multi-resolution fractal
of PTPSA, mBm, and Holder Exponent characterization.

3.3.1

MGMT METHYLATION MODEL

The most frequent features that are selected are the necrosis width in the Z planar, the
histogram entropy of the mBm characterization on the whole tumor, and size ratio between the
enhanced tumor and the necrosis. The necrosis width in the Z planar, the histogram entropy of the
mBm characterization on the whole tumor features are significantly (ANOVA test, p-value < 0.05)
associated with methylated MGMT, whereas the size ratio between enhanced tumor and necrosis
is associated significantly with un-methylated MGMT as shown in Figure 3a.
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(a)

(b)
Figure 3. MGMT methylation models. a) Distribution of the most selected features in
discriminating MGMT mutated and WT, and b) MGMT prediction model performance using the
train and test partitions with and without fractal texture features. Error bars represent standard
deviation. The asterisk * illustrates the significant difference between two measurements.
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The LOOCV performance and the prediction performance on the testing set for predicting
the MGMT methylation status using imaging features are illustrated in Table 2 and Figure 3b. The
prediction performance using the test partitions achieves an AUC, a sensitivity, and a specificity
of 0. 0.83±0.04, 0.93±0.05, and 0.73±0.13, respectively.
Removal of our fractal and multi-resolution fractal features from the MGMT methylation
prediction model has an effect on the prediction performance on the testing set. AUC and
specificity drop significantly (ANOVA test, p-value = 0.003, and 0.01, respectively) when the
fractal features are removed (Figure 3b).

Table 2. LOO cross-validated performance of the outer-loop, and the predictive/test
performance of the different LGG molecular prediction models.
CrossValidated
performance
MGMT
Methylation
IDH mutation
1p/19q
codeletion
ATRX
mutation
TERT

n
repetition

With fractal & multi-resolution

Without fractal & multi-resolution

fractal features

fractal features

AUC.

Sens.

Spec.

AUC.

Sens.

Spec.

11

0.86±0.03

0.88±0.02

0.80±0.09

0.87±0.04

0.90±0.02

0.66±0.10

13

0.85±0.04

0.90±0.03

0.75±0.05

0.79±0.07

0.89±0.08

0.75±0.07

15

0.83±0.03

0.78±0.08

0.83±0.03

0.80±0.05

0.63±0.08

0.87±0.02

10

0.77±0.06

0.62±0.09

0.80±0.03

0.80±0.04

0.77±0.06

0.76±0.03

14

0.82±0.04

0.70±0.06

0.83±0.04

0.82±0.04

0.82±0.04

0.76±0.05

11

0.83±0.04

0.93±0.05

0.73±0.13

0.70±0.12

0.90±0.07

0.50±0.24

13

0.84±0.03

0.90±0.06

0.79±0.09

0.75±0.07

0.83±0.11

0.66±0.18

15

0.80±0.04

0.75±0.08

0.85±0.06

0.75±0.07

0.67±0.12

0.84±0.10

10

0.70±0.09

0.69±0.06

0.83±0.10

0.66±0.10

0.65±0.16

0.68±0.18

14

0.82±0.04

0.77±0.12

0.86±0.09

0.78±0.07

0.77±0.11

0.79±0.11

Prediction/test
Performance
MGMT
Methylation
IDH mutation
1p/19q
codeletion
ATRX
mutation
TERT
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3.3.2

IDH MUTATION MODEL

Our analysis reveals that the tumor correlation, the vertical orientation of edema major axis
(the angle between the edema major axis and the vertical axis), the size ratio between the enhanced
tumor and the necrosis, and the complexity of the holder exponent of the tumor are among the
most frequently selected features to predict IDH-mutated status in LGG. Higher values of the
complexity of holder exponent of the tumor, the size ratio between the enhanced tumor and the
necrosis, and higher values of the vertical orientation of edema major axis associate significantly
(ANOVA test, p-value < 0.005) with WT IDH status, whereas the tumor correlation associates
significantly (ANOVA test, p-value < 0.005) with mutated IDH status as illustrated in Figure 4a.
Figure 4b shows the clustering of IDH status using the most frequent features in Figure 4a. The
clustering between the mutated IDH and WT IDH is demonstrated using t-Distributed Stochastic
Neighbor Embedding (tSNE) [132].
In addition, the tumor correlation, the vertical orientation of edema major axis, and the
complexity of holder exponent of the tumor features carry a hazard ratio [HR] of 0.562 (95% CI,
0.381-0.828), 2.655 (95% CI, 1.617-4.36), and 1.553 (95% CI, 1.165-2.07) with likelihood ratio
test p-value = 0.005, 0.0001, 0.008, respectively. Because these features are continuous features,
the HRs interpolate as follows: the risk of death increases (or decreases if HR<1) by (HR-1) ×100%
for every 1-standard deviation increase in that feature. The LOOCV and the test performance of
the proposed IDH models are illustrated in Table 2. The prediction performance using the testing
partitions achieves an AUC, sensitivity, and specificity of 0.84±0.03, 0.90±0.06, and 0.79±0.09,
respectively. Note that the AUC and specificity of the IDH status prediction model drop
significantly to 0.75±0.07 and 0.66±0.18 (ANOVA test, p = 0.0001 and p = 0.028, respectively)
after removing features extracted from texture extracted from fractal and the multi-resolution
modeling (Figure 4c).
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(a)
Figure 4. IDH models. a) Distribution of the most selected features in discriminating
among IDH mutated and WT cases in LGG, b) 2-D t-Distributed Stochastic Neighbor Embedding
(t-SNE) visualization using only the 4 features in A, and c) Performance comparison of IDH
prediction model using the train and test partitions with and without fractal features. Error bars
represent 2 standard deviations. The asterisk * illustrates the significant difference between two
measurements.
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(b)

(c)
Figure 4. (continued)
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3.3.3

1P/19Q CODELETION MODEL

The necrosis upper-left bounding box location, the histogram entropy of mBm
characterization of the whole tumor, and the horizontal coordinate of necrosis centroid are the most
frequent optimum features that are selected in our proposed 1p/19q codeletion models. These three
features show significance (ANOVA test, p-value < 0.0001) associated with the existence of the
1p/19q codeletion. Our analysis shows frontal tumors are associated significantly (ANOVA test,
p-value < 0.0001) with 1p/19q codeletion mutations (Figure 5.a). The performance of the proposed
codeletion prediction LOOCV model is illustrated in Table 2. The 1p/19q codeletion performance
using the test partitions achieves an AUC of 0.80±0.04, a sensitivity of 0.75±0.08, and a specificity
of 0.85±0.06. In addition, the efficacy of our fractal and multi-resolution fractal texture features
on the performance of the codeletion prediction model is significant as shown in Figure 5b and
Table 2. The AUC and the sensitivity of the codeletion prediction model drop significantly
(ANOVA test, p-value of 0.024 and 0.029, respectively) after removing features extracted from
our fractal and multi-resolution fractal features in the 1p/19q codeletion prediction model to
0.75±0.07 and 0.67±0.12 (without fractal features). Figure 5c illustrates the location of the
centroid and the upper-left bounding box of the necrosis. The histogram entropy of mBm of the
tumor volume offers HR of 0.59 per standard deviation (95% CI, 0.35-0.97) with a likelihood ratio
test p-value of 0.037.
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(a)

(b)
Figure 5. 1p/19q codeletion models. a) Distribution of the most selected features in
discriminating 1p/19q codeletion and non-codeletion, b) Performance comparison of codeletion
classifier models using the train and test partitions with and without fractal features. c) Example of
FLAIR images illustrates the location of the necrosis centroid and the upper-left location of the
necrosis bounding-box. Error bars represent 2 standard deviations. The asterisk * illustrates the
significant difference between two measurements.
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Bounding-box feature

Necrosis centroid feature
(c)

Figure 5. (continued)

3.3.4

ATRX MUTATION MODEL

The information content of correlation and the histogram mean of the tumor volume of the
most frequently selected features are employed in the XGBoost model to train and predict ATRX
status. The distribution of the most frequent features is illustrated in Figure 6.a. Higher values of
information of correlation are associated significantly (ANOVA test, p-value < 0.001) with ATRX
wildtype, whereas higher values of histogram mean are associated significantly (ANOVA test, pvalue < 0.001) with mutated ATRX. The ATRX prediction model achieves prediction performance
of an AUC of 0.70±0.09, a sensitivity of 0.70±0.06, and a specificity of 0.83±0.10 using the test
partitions. Removing features extracted from our fractal and multi-resolution fractal modeling from
the ATRX prediction model has a significance specificity drop to 0.68±0.18 performance of the
model with p-value = 0.03 (ANOVA test) as shown in Figure 6b.
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(a)
Figure 6. Distribution of the most selected feature in discriminating a) mutated ATRX and
WT, b) Performance comparison of ATRX classifier models using the train and test partitions with
and without fractal features. Error bars represent 2 standard deviations. The asterisk * illustrates the
significant difference between two measurements, and c) mutated TERT and WT.
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(b)

(c)
Figure 6. (continued)
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3.3.5

TERT MUTATION MODEL

After reviewing the most frequently selected imaging features of the TERT mutation
prediction model, we notice that the information content of correlation of the tumor volume, the
edema upper-left bounding box location, and the inverse difference moment of HE characterization
of tumor volume are the most frequently selected features (Figure 6c). The inverse difference
moment of HE characterization of tumor volume offers HR of 0.612 per standard deviation (95%
CI, 0.405-0.924) with a likelihood ratio test p-value = 0.027. The TERT prediction models’
performances are illustrated in Table 2. The TERT prediction performance using the test partitions
achieves an AUC of 0.82±0.04, a sensitivity of 0.77±0.12, and a specificity of 0.86±0.09,
respectively. Removing our fractal and multi-resolution fractal texture modeling has no significant
effect on the TERT performance of prediction models when using the test partitions as shown in
Table 2.

3.4 DISCUSSIONS

The 2016 WHO classification of diffuse LGGs heavily weighs molecular mutations
classifying primary brain tumors with particular importance assigned to IDH mutation, 1p/19q
codeletion, ATRX mutation, TERT mutations, and MGMT methylation. Our study on diffuse LGG
is largely able to predict the presence of these important molecular mutations based on MR
imaging features. Therefore, prediction of tumor aggressiveness (based on molecular mutations)
may be achieved through non-invasive imaging features as an adjunct to traditional visual
morphologic diagnosis and invasive tissue sampling.
In this work, the number of originally extracted imaging features (six hundred eighty
features) is higher than the number of samples (eighty-one cases) in the training dataset, which
may cause overfitting. To address possible overfitting, we implement feature selection in the
training model that offers a maximum of fifteen selected features. Figure 7 illustrates the effects
of the number of features on the cross-validated performance of the different mutation prediction
models. The average AUC performances and the standard error of the different prediction models
improve when the number of features is greater than 9. Note that the standard error mostly plateaus
when the number of features varies between 9-15 (standard error reflects instability).
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For the fractal and multifractal texture model in Table 2, the AUC predictive performance
of MGMT, 1p/19q codeletion, and ATRX models drop to 0.83±0.04, 0.80±0.04, and 0.70±0.09,
respectively. This statistically non-significant drop in performance (ANOVA test, p-value =
0.076, p-value = 0.073, and p-value = 0.071 respectively) when compared to their AUC crossvalidated performance, may suggest minimal overfitting for these models. The AUC predictive
performances of IDH and TERT models are almost comparable to their cross-validated
performance as shown in Table 2 that suggests there is no overfitting in these two models.
For the non-fractal models in Table 2, the AUC predictive performance of IDH, 1p/19q
codeletion, and TERT models drops to 0.75±0.07, 0.75±0.07, and 0.78±0.07 respectively. This
statistically non-significant drop (ANOVA test, p-value = 0.182, p-value = 0.056, and p-value =
0.062 respectively) when compared to their AUC cross-validated performance, may suggest
minimal overfitting for these models. However, the poor predictive performances of the nonfractal MGMT and non-fractal ATRX models when compared with their non-fractal crossvalidated performances are a sign of overfitting.
Note optimally chosen features in the non-fractal models are not selected by simply
replacing the fractal features with alternate features (or by using the same number of predictors as
in the fractal models). In each mutation model (fractal or non-fractal), RFS (and thus selecting
optimally chosen features) is performed independently. In our implementation of RFS for fractal or
non-fractal models, the possible number of features in the features’ sets could be 2, 3, 5, 7, 9, 11,
13, and 15, respectively. The maximum number of selected features is set to 15 such that the training
samples (81 cases) are at least 5 times the number of features to reduce the possibility of model
overfitting.
Finally, we compare the performances of our prediction models with a list of state-of-theart studies as illustrated in Table 3. However, a direct comparison between the performances of
our proposed models and these studies may not be relevant because of the different datasets.
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(a)

(b)
Figure 7. The effect of number of features on cross-validated performance of the different
mutation models. a) MGMT prediction model, b) IDH prediction model, c) 1p/19q codeletion
prediction model, d) ATRX prediction model, and e) TERT prediction model. The y axis represents
mean AUC of every feature set which is computed from all independent n repetitions, and error bars
represent 2 standard deviations. The x axis represents the number of selected features.

37

(c)

(d)
Figure 7. (continued)
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(e)
Figure 7. (continued)
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(a)

(b)
Figure 8. The effect of thresholding a) the size ratio between the enhanced tumor and
necrosis, b) tumor correlation, and c) vertical orientation of edema major axis around the median.
P-values are computed using the likelihood ratio test.
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(c)
Figure 8. (continued)

Our study on MGMT methylation prediction shows that MGMT methylation correlates
with high values of fractal texture features such as histogram entropy of mBm for tumor volume.
Entropy measures randomness or uncertainty in the tumor. The analysis reveals that high
histogram entropy of mBm associates with the less aggressive methylated MGMT status and
carries HR of 0.579 per standard deviation (95%CI, 0.345, 0.969) with likelihood ratio test p-value
= 0.035. The study further shows that the size ratio between enhanced tumor and necrosis
correlates significantly with un-methylated MGMT, which indicates that the higher the aggressive
MGMT un-methylated LGG, the higher the values of the size ratio.
The MGMT methylation prediction study by Kanas et al. [59] for patients with GBM
reports the size of the tumor with respect to necrosis as one of the significant features. Our analysis
shows that removing the texture features such as fractal and the multi-resolution fractal (of PTPSA,
mBm, and Holder Exponent) characterization is significant on the AUC and specificity
performance of the MGMT methylation model. The GBM study conducted by Kanas et al. [59]
(Table 3) proposes an MGMT prediction model using volumetric, morphological, and locational
MR imaging features, respectively. In our study, we use texture features and volumetric features.
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Moreover, the entire process of the prediction model in our current study including feature
extraction is automated, unlike the proposed work by Kanas et al. [59]. In another study by Han et
al. [99] (Table 3), the authors use a bi-directional convolutional recurrent neural network to predict
MGMT methylation status. A major difference between our MGMT prediction model and the
method proposed by Han et al. [99] is that our model mainly utilizes quantitative imaging features
that can be correlated with tumor biology.
In addition, our IDH mutation prediction model indicates that the tumor correlation
associates significantly with mutated IDH and offers HR of 0.562 per standard deviation with a
likelihood ratio test p-value =0.005. In addition, our analysis shows that the complexity of HE of
enhanced tumor associates significantly with WT IDH status with HR of 1.553 per standard
deviation with a likelihood ratio test p-value =0.008. Complexity is related to the visual
information content and the shape of the object. Texture with higher information content and with
a large number of edges is considered complex [133]. This outcome is in agreement with another
glioma study by Wang et al. [134] which reports that the enhancement patterns predict the
prognosis in IDH1 mutations in Anaplastic gliomas. Our analysis also shows that the size ratio
between enhanced tumor and necrosis is a significant predictive feature of the IDH status. This
feature is also a significant predictor of MGMT status, which can be explained by the fact that
MGMT methylation is associated with IDH status as reported by different studies [14, 135].
The IDH prediction model by Yu et al. [100] (Table 3) uses 110 imaging features and
SVM for Grade II glioma. Even though the dataset we use in the IDH mutation prediction is not
the same as the dataset used by Yu et al. [100], the dataset used in our study is more diverse with
data from both Grade II and III, and this reflects higher reliability of the performance of the IDH
status prediction model.
Furthermore, our study on the 1p/19q codeletion prediction model indicates that the
location of the upper-left necrosis bounding box and horizontal coordinate of the necrosis centroid
(illustrated in Figure 5c) are among the most predictive features. This outcome is in agreement
with different studies [136-138] which report that gliomas with 1p/19q codeletion are associated
with the tumor location. In addition, our analysis shows that higher values of histogram entropy of
mBm texture of tumor volume associate significantly with the existence of 1p/19q codeletion.
Moreover, our analysis reveals that removing the texture representation of fractal and multiresolution fractal from the 1p/19q codeletion prediction model decreases the AUC and specificity
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significantly. The test prediction performance of the 1p/19q codeletion prediction model drops
(after removing the fractal features). A study by Akkus et al. [102] (Table 3) with LGG patients
(where each patient has 3 MRI slices) proposes 1p/19q codeletion prediction using a convolutional
neural network (CNN). Their method achieves better sensitivity; however, our method achieves
slightly better specificity. In addition, Akkus et al. [102] do not consider the global information of
the tumor, since their dataset uses only 3 slices of the MRI sequence of each patient as input, not
the whole volume of the tumor.
Our analysis of ATRX-status prediction shows that tumor information-measure of
correlation imaging feature and histogram mean tumor volume are the most frequently selected
features. Higher values of information-measure of correlation associate significantly with WT
ATRX status. This is in agreement with an ATRX mutation prediction study by Li et al. [58] (Table
3) in patients with a low-grade glioma, where the authors use MRI texture feature and the LASSO
regression model. In their model, information-measure of correlation is one of the features that is
used to predict ATRX mutation. In addition, our analysis shows that the tumor informationmeasure of correlation is one of the most frequent features in the TERT model as well. This can be
explained by the fact that ATRX and TERT mutations are mutually exclusive.
The TERT prediction analysis shows that tumor information-measure of correlation and
upper-left edema bounding box are the most frequently selected features. Higher values of these
two features are significantly associated with mutated TERT status. The information-measure of
correlation assesses the correlation/dependency between two gray-levels using mutual information
content. Higher values of information-measure of correlation are associated with mutated TERT.
In addition, our analysis suggests that the higher values of Inverse difference moment of HE
associates significantly with WT TERT and offers HR = 0.612 per standard deviation with a
likelihood ratio test, p-value = 0.03. Inverse difference moment measures local homogeneity. High
values of inverse difference moment of an HE tumor predict the less aggressive WT TERT.
Overall, our analysis shows that the necrosis location and the necrosis volume-related
features are very important (most frequently selected features) in MGMT, IDH, and 1p/19q
codeletion prediction. Edema volume-related features are very important in IDH and TERT
prediction models. Fractal features have a significant effect on MGMT, IDH, 1p/19q codeletion,
and ATRX prediction models. Further analysis of the most frequent features in each prediction
model indicates that the effect of thresholding the value of the standardized feature around the
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median can stratify the 108 cases significantly (log-rank test, p-value < 0.05) into two survival
groups (Figure 8a-c). The features and the median survival of each group are:
•

the size ratio between the enhanced tumor and necrosis stratifies the 108 cases into two groups
with a median survival of 87.4 months vs 30.7 months,

•

the correlation of the tumor volume stratifies the 108 cases into two groups with a median
survival of 114 months vs 46 months,

•

and the vertical orientation of edema major axis stratifies the 108 cases into two groups with a
median survival of 114 vs 44 months.
In summary, this study presents molecular prediction model designs from traditional MRI

data based on the 2016 update of the WHO classification of LGG of the CNS. Our prediction
model performance shows promise when compared to other methods and models in the literature.
An association among computed MR imaging features and the molecular mutations LGG was
established. The methods discussed in our study are important steps towards non-invasive imaging
classification of diffuse LGG based on molecular mutations prior to invasive tissue sampling. In
this work for the first time in the literature, we hypothesize that fractal and multi-resolution fractal
features have an association with molecular prediction. The feature selection using RFS and the
subsequent prediction results in Table 1 confirm our hypothesis by showing the efficacy of these
fractal features in glioma prediction. Therefore, this work may be considered as a validation of
previously hypothesized fractal biomarkers and, hence, may have the potential for generalizability
for other types of tumors.
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Table 3. Comparison between our proposed molecular mutations models and state-of-the
art glioma grading models.
Our Proposed Prediction Models

Other Models

108 LGG (75% training, 25 testing)
Test Performance (using
Models

testing sets)

n

Study (dataset)

Performance

AUC, Sens., Spec.
Kanas et al.[59] (86
GBM patients)
MGMT

0.83

0.93

0.73

±

±

±

0.04

0.05

0.13

11

Han et al. [99] (159
LGG; 70% training,
15% validation, and
15% testing)

IDH

0.84

0.90

0.79

±

±

±

0.03

0.06

0.09

Yu et al.[100] (110
13

training, 30
independent
validation)

Acc, Sens., Spec.
0.736, 0.85, 0.66

AUC, Accuracy, Prec., Recall
Testing: 0.61, 0.62, 0.67, 0.67
Validation: 0.66, 0.67, .67,0.73

Accuracy, AUC, Sens., Spec.
Training: 0.80, 0.86, 0.83, 0.74
Validation: 0.83, 0.79, 0.88, 0.67

Akkus et al.[102]
1p/19q codel.

0.80

0.75

0.85

±

±

±

0.04

0.08

0.06

(159 LGG (252
15

slices), validation (68
slices), and testing

Accuracy Sens., spec.
0. 877, 0.933, 0.822

(90 slices)).

ATRX

0.70

0.69

0.83

±

±

±

0.09

0.06

0.10

Li et al.[58] (95
10

LGG, 63 training, 32
validation, and 91
external validation

Accuracy, AUC, Sens. Spec.
Validation: 0.938,
0.925,0.83.3,1.00
External: 0.769, 0.725, 0.571,
0.857
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CHAPTER 4

GLIOMA GRADING AND PREDICTION USING JOINT MODELING OF RNA
SEQUENCING AND RADIOMICS IN A NEGATIVE BINOMIAL DISTRIBUTION

4.1 CHAPTER OVERVIEW

RNA sequencing (RNAseq) is a recent technology that profiles gene expression by
measuring the relative frequency of the RNAseq reads. Contemporary literature lacks appropriate
modeling for RNAseq distribution where the model is adaptive and also preserves the nature of
RNAseq read counts data for glioma grading and prediction. Negative Binomial (NB) distribution
may be useful to model RNAseq read counts data that addresses these shortcomings. In addition
to RNAseq read counts data, radiomics has long played a pivotal role in current radiology practice
such as disease diagnosis, monitoring, and treatment planning.
In this study, we propose an RNA-radiomics (henceforth, radiogenomics) -NB model for
glioma grading and prediction. Our radiogenomics-NB model is developed based on differentially
expressed RNAseq and selected radiomics/volumetric features which characterize the tumor
volume and its sub-regions. The NB distribution is fitted to RNAseq counts data, and a log-linear
regression model is assumed to link between the estimated NB mean and radiomics. Three
radiogenomics-NB molecular mutation models (e.g., IDH mutation, 1p/19q codeletion, and ATRX
mutation) are investigated. Additionally, we explore the gender-specific effect on the
radiogenomics-NB models.
Finally, we compare the performance of the three mutation prediction radiogenomics-NB
models with different well-known methods in the literature: Negative Binomial Linear
Discriminant Analysis (NBLDA), differentially expressed RNAseq with Random Forest (RFgenomics), radiomics and differentially expressed RNAseq with Random Forest (RFradiogenomics), and voom-based count transformation combined with the nearest shrinkage
classifier (VoomNSC). Our analysis shows that the proposed radiogenomics-NB model
significantly outperforms (ANOVA test, p-value < 0.05) for prediction of IDH and ATRX
mutations and offers similar performance for prediction of 1p/19q codeletion, when compared to
these competing models in the literature, respectively.
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4.2 PREDICTION USING NEGATIVE BINOMIAL REGRESSION MODEL

In this study, we propose a radiogenomics-NB method for glioma molecular grading and
prediction. Figure 9 illustrates an overall flow diagram of the proposed radiogenomics model. In
Figure 9a, we fit NB distribution to RNAseq read counts data of the training dataset and estimate
the model mean and dispersion parameter. Then, we use the estimated mean along with the
predictor radiomics vector in a log-linear regression model to estimate the model regression
coefficients. The dispersion parameter is estimated using the weighted likelihood empirical Bayes
[115]. In Figure 9b, the estimated parameters of regression coefficients and the dispersion
parameters along with the sample radiomics and its RNAseq read counts are utilized to predict the
class label of a future test sample. A complete mathematical derivation of the radiogenomics-NB
model is presented in the following subsection.
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(a)

(b)
Figure 9. Overall Flow diagram of the proposed radiogenomics-NB prediction model.a)
radiogenomics-NB model utilizing the training data. b) class prediction of a test sample using the
developed radiogenomics-NB model.

4.2.1

Prediction using Negative Binomial regression model

To fuse radiomics with RNAseq read counts data in an NB model, the following
parametrization is defined:
Let 𝐶𝐶 be the total number of classes, and 𝐼𝐼𝑐𝑐 ∈ (1, . . . , 𝑛𝑛𝑐𝑐 ) the indices of samples in class c

for 𝑐𝑐 = 1, . . . , 𝐶𝐶. The examples of different classes include:
o IDH mutated vs wildtype IDH (𝐶𝐶 = 2),

o 1p/19q codeletion: codeletion vs non-codeletion (in this case 𝐶𝐶 = 2),
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o Mutated ATRX vs wildtype (in this case 𝐶𝐶 = 2).

let 𝑌𝑌𝑖𝑖 = (𝑦𝑦𝑖𝑖1 , 𝑦𝑦𝑖𝑖2 , . . . , 𝑦𝑦𝑖𝑖𝑖𝑖 ) be the RNAseq read counts training sample in the class label c

and 𝐺𝐺 is the total number of RNAseq. The purpose of this study is to predict the class label 𝑐𝑐 of a
future observation 𝑌𝑌𝑡𝑡 using training samples associated with known class labels: 𝑝𝑝( 𝑐𝑐|𝑌𝑌𝑡𝑡 ) ∝

𝑝𝑝(𝑌𝑌𝑡𝑡 |𝑐𝑐)𝑝𝑝𝑐𝑐 , where 𝑝𝑝𝑐𝑐 is the probability of class c. Using Bayes’ rule, we have,
𝑝𝑝( 𝑐𝑐|𝑌𝑌𝑖𝑖 ) ∝ 𝑝𝑝(𝑌𝑌𝑖𝑖 |𝑐𝑐)𝑝𝑝c ;

(2)

where 𝑝𝑝(𝑌𝑌𝑖𝑖 | 𝑐𝑐) is the pdf of the sample 𝑌𝑌𝑖𝑖 in class c, and 𝑝𝑝c is the prior probability that one sample

comes from class c. The pdf of class-specific c of RNAseq read counts of sample 𝑌𝑌𝑖𝑖 and gene 𝑔𝑔 is
𝑃𝑃(𝑌𝑌𝑖𝑖𝑖𝑖 = 𝑦𝑦𝑖𝑖𝑖𝑖 |𝑍𝑍 = 𝑐𝑐) =

−1 +𝑦𝑦 )
Γ(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖
−1 )𝑦𝑦 !
Γ(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖

𝜙𝜙𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖

(1+𝜙𝜙

𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖

1

)𝑦𝑦𝑖𝑖𝑖𝑖 (1+𝜙𝜙

𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖

−1

)𝜙𝜙𝑔𝑔 .

(3)

In this parameterization, 𝑌𝑌𝑖𝑖𝑖𝑖 represents a count response of RNAseq, where 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 represents

the mean, 𝜙𝜙𝑔𝑔 represents the dispersion parameter, 𝐸𝐸(𝑌𝑌𝑖𝑖𝑖𝑖 ) = 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 , and 𝑉𝑉𝑉𝑉𝑉𝑉(𝑌𝑌𝑖𝑖𝑖𝑖 ) = 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 + 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 𝜙𝜙𝑔𝑔2 .
Note we assume that all RNAseq are independent of each other, so we have,
𝑝𝑝(𝑌𝑌𝑖𝑖 |𝑍𝑍 = 𝑐𝑐) = ∏𝐺𝐺𝑔𝑔=1 𝑃𝑃(𝑌𝑌𝑖𝑖𝑖𝑖 = 𝑦𝑦𝑖𝑖𝑖𝑖 ).

(4)

Evaluating equation 2 requires an estimation of 𝑝𝑝(𝑌𝑌𝑖𝑖 |𝑐𝑐) and 𝑝𝑝c . The model in equation 3

states that 𝑌𝑌𝑖𝑖𝑖𝑖 ~𝑁𝑁𝑁𝑁(𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 , 𝜙𝜙𝑔𝑔 ). We first estimate 𝜙𝜙1 , 𝜙𝜙2 , . . . , 𝜙𝜙𝐺𝐺 and 𝜇𝜇𝑖𝑖1𝑐𝑐 , 𝜇𝜇𝑖𝑖2𝑐𝑐 , . . . , 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 of all the

training samples 𝑛𝑛𝑐𝑐 , and all RNAseq 𝐺𝐺. The mean is estimated as 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 = 𝑠𝑠𝑖𝑖𝑖𝑖 𝜆𝜆𝑔𝑔𝑔𝑔 , where 𝑠𝑠𝑖𝑖𝑖𝑖 is the

size factor [139, 140] which is used to scale RNAseq counts for the 𝑖𝑖𝑖𝑖ℎ sample (in class c), 𝜆𝜆𝑔𝑔𝑔𝑔 is

the total number of reads of RNAseq 𝑔𝑔 across all samples in class c. Regarding the prior 𝑝𝑝c , we

assume all classes are equally likely 𝑝𝑝𝑐𝑐 = 1⁄𝐶𝐶 . Note that 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 , 𝑠𝑠𝑖𝑖𝑖𝑖 , 𝑎𝑎𝑎𝑎𝑎𝑎 𝜆𝜆𝑔𝑔𝑔𝑔 are estimated for each
class 𝑐𝑐.

Next, plugging these estimates into equation 3 and using the assumption of independent

RNAseq, equation 2 yields,
𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑐𝑐|𝑌𝑌𝑖𝑖 )) = 𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑌𝑌𝑖𝑖 |𝑐𝑐) + 𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝𝑐𝑐 ).

(5)
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The log-likelihood 𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑌𝑌𝑖𝑖 |𝑐𝑐)) is written as,
𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑌𝑌𝑖𝑖 |𝑐𝑐)) = 𝑙𝑙𝑙𝑙𝑙𝑙(∏𝐺𝐺𝑔𝑔=1 𝑃𝑃(𝑌𝑌𝑖𝑖𝑖𝑖 = 𝑦𝑦𝑖𝑖𝑖𝑖 |𝑐𝑐)) = 𝑙𝑙𝑙𝑙𝑙𝑙(∏𝐺𝐺𝑔𝑔=1
1

(1+𝜙𝜙

𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖

−1

)𝜙𝜙𝑔𝑔 ).

−1 +𝑦𝑦 )
Γ(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖
−1 )𝑦𝑦 !
Γ(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖

𝜙𝜙𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖

× (1+𝜙𝜙

𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖

)𝑦𝑦𝑖𝑖𝑖𝑖 ×
(6)

Equation 6 can be written as,

𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑌𝑌𝑖𝑖 |𝑐𝑐)) = ∑𝐺𝐺𝑔𝑔=1 𝑙𝑙𝑙𝑙𝑙𝑙(

𝜙𝜙𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖

1+𝜙𝜙𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖

1

)𝑦𝑦𝑖𝑖𝑖𝑖 + ∑𝐺𝐺𝑔𝑔=1 𝑙𝑙𝑙𝑙𝑙𝑙(1+𝜙𝜙

𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖

−1

)𝜙𝜙𝑔𝑔 + ∑𝐺𝐺𝑔𝑔=1 𝑙𝑙𝑙𝑙𝑙𝑙(

−1 +𝑦𝑦 )
Γ(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖
−1 )𝑦𝑦 !
Γ(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖

).

(7)

Rewriting equation 7 yields,
1

𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑌𝑌𝑖𝑖 |𝑐𝑐)) = ∑𝐺𝐺𝑔𝑔=1 𝑦𝑦𝑖𝑖𝑖𝑖 𝑙𝑙𝑙𝑙𝑙𝑙(𝜙𝜙𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 ) − ∑𝐺𝐺𝑔𝑔=1 𝑦𝑦𝑖𝑖𝑖𝑖 𝑙𝑙𝑙𝑙𝑙𝑙(1 + 𝜙𝜙𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 ) − ∑𝐺𝐺𝑔𝑔=1 𝜙𝜙 𝑙𝑙𝑙𝑙𝑙𝑙(1 +
𝜙𝜙𝑔𝑔 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 ) + ∑𝐺𝐺𝑔𝑔=1 𝑙𝑙𝑙𝑙𝑙𝑙(

−1 +𝑦𝑦 )
𝛤𝛤(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖
−1 )𝑦𝑦 !
𝛤𝛤(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖

).

𝑔𝑔

(8)

The proposed NB model of genomics relates to the radiomics (imaging features) 𝑿𝑿 through

the mean parameters 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 (estimated mean of an 𝑖𝑖𝑖𝑖ℎ sample and RNAseq g in class c). We assume
a log-linear regression model for estimated the mean 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 in terms of the radiomics (imaging
features) as follows:

𝑙𝑙𝑙𝑙𝑙𝑙(𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 ) = 𝑋𝑋𝑖𝑖 𝛽𝛽𝑔𝑔𝑔𝑔 ;

𝑙𝑙𝑜𝑜𝑜𝑜(𝑠𝑠𝑖𝑖𝑖𝑖 𝜆𝜆𝑔𝑔𝑔𝑔 ) = 𝑋𝑋𝑖𝑖 𝛽𝛽𝑔𝑔𝑔𝑔 ;

(9.a)
(9.b)

where 𝑋𝑋𝑖𝑖 is a 𝑝𝑝-dimensional of radiomics, 𝛽𝛽𝑔𝑔𝑔𝑔 is a 𝑝𝑝-dimensional vector of unknown regression
coefficients (translate the relationship between 𝑋𝑋 and 𝑌𝑌 through 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 ). The estimation of 𝛽𝛽𝑔𝑔𝑔𝑔

depends on class 𝑐𝑐 and gene 𝑔𝑔 of the 𝑖𝑖𝑖𝑖ℎ sample. Hence, if there are two classes, we will need to
estimate 𝛽𝛽𝑔𝑔1 and 𝛽𝛽𝑔𝑔2 (one from each class). Plugging equation 9.a into equation 8, yields,
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𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑌𝑌𝑖𝑖 |𝑐𝑐)) = ∑𝐺𝐺𝑔𝑔=1 𝑦𝑦𝑖𝑖𝑖𝑖 𝑙𝑙𝑙𝑙𝑙𝑙(𝜙𝜙𝑔𝑔 𝑒𝑒𝑒𝑒𝑒𝑒(𝑋𝑋𝑖𝑖 𝛽𝛽𝑔𝑔𝑔𝑔 + 𝜀𝜀)) − ∑𝐺𝐺𝑔𝑔=1 𝑦𝑦𝑖𝑖𝑖𝑖 𝑙𝑙𝑙𝑙𝑙𝑙(1 + 𝜙𝜙𝑔𝑔 𝑒𝑒𝑒𝑒𝑒𝑒(𝑋𝑋𝑖𝑖 𝛽𝛽𝑔𝑔𝑔𝑔 +
1

𝜀𝜀)) − ∑𝐺𝐺𝑔𝑔=1 𝜙𝜙 𝑙𝑙𝑙𝑙𝑙𝑙(1 + 𝜙𝜙𝑔𝑔 𝑒𝑒𝑒𝑒𝑒𝑒(𝑋𝑋𝑖𝑖 𝛽𝛽𝑔𝑔𝑔𝑔 + 𝜀𝜀)) + ∑𝐺𝐺𝑔𝑔=1 𝑙𝑙𝑙𝑙𝑙𝑙(
𝑔𝑔

−1 +𝑦𝑦 )
𝛤𝛤(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖
−1 )𝑦𝑦 !
𝛤𝛤(𝜙𝜙𝑔𝑔
𝑖𝑖𝑖𝑖

).

(10)

Using the estimated 𝛽𝛽̂𝑔𝑔𝑔𝑔 , and 𝜙𝜙�𝑔𝑔 from the training data, if we classify a test observation 𝑌𝑌𝑡𝑡

as follows,

𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑍𝑍 = 𝑐𝑐|𝑌𝑌𝑡𝑡 )) = 𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑌𝑌𝑡𝑡 |𝐶𝐶 = 𝑐𝑐) + 𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝𝑐𝑐 )

(11)

and,
𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝(𝑐𝑐|𝑌𝑌𝑡𝑡 )) = ∑𝐺𝐺𝑔𝑔=1 𝑦𝑦𝑡𝑡𝑡𝑡 𝑙𝑙𝑙𝑙𝑙𝑙(𝜙𝜙�𝑔𝑔 𝑒𝑒𝑒𝑒𝑒𝑒(𝑋𝑋𝑡𝑡 𝛽𝛽̂𝑔𝑔𝑔𝑔 )) − ∑𝐺𝐺𝑔𝑔=1 𝑦𝑦𝑡𝑡𝑡𝑡 𝑙𝑙𝑙𝑙𝑙𝑙(1 + 𝜙𝜙�𝑔𝑔 𝑒𝑒𝑒𝑒𝑒𝑒(𝑋𝑋𝑡𝑡 𝛽𝛽̂𝑔𝑔𝑔𝑔 )) −
∑𝐺𝐺𝑔𝑔=1

4.2.2

1

𝜙𝜙𝑔𝑔

𝑙𝑙𝑙𝑙𝑙𝑙(1 + 𝜙𝜙�𝑔𝑔 𝑒𝑒𝑒𝑒𝑒𝑒(𝑋𝑋𝑡𝑡 𝛽𝛽̂𝑔𝑔𝑔𝑔 )) + ∑𝐺𝐺𝑔𝑔=1 𝑙𝑙𝑙𝑙𝑙𝑙(

−1 +𝑦𝑦 )
� 𝑔𝑔
𝛤𝛤(𝜙𝜙
𝑡𝑡𝑡𝑡
−1 )𝑦𝑦 ! )
� 𝑔𝑔
𝛤𝛤(𝜙𝜙
𝑡𝑡𝑡𝑡

+ 𝑙𝑙𝑙𝑙𝑙𝑙(𝑝𝑝𝑐𝑐 ).

(12)

ESTIMATING DISPERSION PARAMETER 𝝓𝝓𝒈𝒈 USING WEIGHTED

LIKELIHOOD EMPIRICAL BAYES.

Various methods for estimating the dispersion parameter 𝜙𝜙𝑔𝑔 are proposed in the literature.

EdgeR applies a weighted conditional log-likelihood method to estimate dispersion parameter

[115]. The weighted conditional log-likelihood (WL) for 𝜙𝜙𝑔𝑔 is defined as a weighted combination

of the individual (per-gene) likelihood 𝑙𝑙𝑔𝑔 (𝜙𝜙𝑔𝑔 ) and common 𝑙𝑙𝐶𝐶 (𝜙𝜙𝑔𝑔 ) likelihood:
𝑊𝑊𝑊𝑊(𝜙𝜙�𝑔𝑔 ) = 𝑙𝑙𝑔𝑔 (𝜙𝜙𝑔𝑔 ) + 𝛼𝛼𝑙𝑙𝐶𝐶 (𝜙𝜙𝑔𝑔 );

(13)

where 𝛼𝛼 is the weight of 𝑙𝑙𝐶𝐶 (𝜙𝜙𝑔𝑔 ).
In EdgeR, 𝜙𝜙�𝑔𝑔 is assumed to be normally distributed with means 𝜙𝜙𝑔𝑔 and known variance

𝜏𝜏 2 , and has the following hierarchical model:

𝜙𝜙�𝑔𝑔 |𝜙𝜙𝑔𝑔 ~𝑁𝑁(𝜙𝜙𝑔𝑔 , 𝜏𝜏 2 ), 𝑎𝑎𝑎𝑎𝑎𝑎 𝜙𝜙𝑔𝑔 ~𝑁𝑁(𝜙𝜙0 , 𝜏𝜏02 ).

(14)
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Under this hierarchical normal model, the maximum weighted conditional log-likelihood
estimator is given as:
�

2

𝐺𝐺

�

2

𝜙𝜙𝑔𝑔 ⁄𝜏𝜏 +𝛼𝛼 ∑ 𝜙𝜙 �𝜏𝜏
𝑊𝑊𝑊𝑊
𝜙𝜙�𝑔𝑔 = ⁄ 2 +𝛼𝛼 ∑𝐺𝐺𝑖𝑖=11⁄𝑖𝑖 𝜏𝜏2𝑖𝑖 ;
1 𝜏𝜏

𝑖𝑖=1

𝑖𝑖

(15)

where,
1⁄𝛼𝛼 = ∑𝐺𝐺𝑖𝑖=1 𝜏𝜏02 ⁄𝜏𝜏𝑖𝑖2 ,

(16)

and,

𝜙𝜙0 = 𝜙𝜙�0 =
4.2.3

2
�
∑𝐺𝐺
𝑖𝑖=1𝜙𝜙𝑖𝑖 �𝜏𝜏𝑖𝑖
2
∑𝐺𝐺
𝑖𝑖=11⁄𝜏𝜏𝑖𝑖

.

(17)

COMPUTATION OF THE MEAN OF RNASEQ 𝝁𝝁𝒊𝒊𝒈𝒈𝒄𝒄

The size factor 𝑠𝑠𝑖𝑖𝑖𝑖 of sample 𝑖𝑖 and class c is the total number of RNAseq read counts of

that sample divided by the total number of all RNAseq read counts across all training samples (in
class 𝑐𝑐). The size factor estimation is vital to account for the different sequencing depth (library
size) that may be used to sequence different samples.

The mean 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 of sample 𝑖𝑖 and RNAseq 𝑔𝑔 in class c is then estimated as 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 = 𝑠𝑠𝑖𝑖𝑖𝑖 𝜆𝜆𝑔𝑔𝑔𝑔 ,

where 𝜆𝜆𝑔𝑔𝑔𝑔 is the total number of reads per RNAseq in class c. Using the estimated value of 𝜇𝜇𝑖𝑖𝑖𝑖𝑖𝑖 ,

the values of 𝛽𝛽𝑔𝑔𝑔𝑔 are computed using equation 9.a. The algorithm in Figure 10 illustrates the steps
of estimating the different parameters in the radiogenomics Negative Binomial classification
model.
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Figure 10. Algorithm of prediction using radiogenomics Negative Binomial classification
model.

4.3 EXPERIMENTAL RESULTS

4.3.1

DATASET

The dataset in this study consists of 108 pre-operative LGG patients that are described in
[123, 124, 141]. Four sequences of the MRI are provided with the dataset: pre-contrast T1weighted (T1), post-contrast T1-weighted (T1Gd), T2-weighted (T2), and T2 Fluid Attenuated
Inversion Recovery (FLAIR). These scans are skull-stripped, re-sampled to 1 mm3 resolution, and
co-registered to the T1 template. The dataset provides the segmented sub-regions of the LGG:
Gadolinium enhanced tumor (ET), the peritumoral edema (ED), and the necrosis along with noncontrast enhancing tumor (NCR/NET). RNAseq read counts data (with a total number of 56830
RNAseq), molecular alterations (IDH mutation, 1p/19q codeletion, and ATRX), grade (II and III),
and the clinical dataset is downloaded from the Genomic Data Commons Data Portal
(https://portal.gdc.cancer.gov/). The clinical dataset is de-identified by the Health Insurance
Portability and Accountability Act of 1996 (HIPAA). The distribution of the data is as follows: (i)
IDH mutation: 85 Mutant and 23 wildtype (WT), (ii) 1p/19q codeletion: 27 codeletion and 81 non-
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codeletion, and (iii) ATRX status: 43 Mutant and 65 WT. The range of the patients’ age at diagnosis
is 20 – 75 years, and the median age is 46.5 years.

4.3.2

DATA PREPARATION

In this study of glioma molecular grading and prediction, for the dataset of 108 LGG cases,
we obtain two types of features (i.e. radiomics and RNAseq read counts data) and 3 molecular
mutation types. The three molecular types are (i) IDH mutation: 85 Mutant and 23 wildtype (WT),
(ii) 1p/19q codeletion: 27 codeletion and 81 non-codeletion, and (iii) ATRX mutation: 43 Mutant
and 65 WT.
We first filter RNAseq read counts to remove RNAseq with a very low value of read counts
before performing any statistical analysis. RNAseq with very low read counts holds very little
information because an RNAseq of biological importance needs to be expressed at some minimal
level. We utilize a quantile filter [142] with a quantile threshold of 0.25. This step returns each
RNAseq that has a mean across all samples higher than the defined quantile threshold of 0.25.
Then, we reduce the number of RNAseq that are used in the radiogenomics-NB models by utilizing
EdgeR [116] to extract the differentially expressed RNAseq (DERs). DERs reflect the significance
of a gene in a certain biological condition. In this study, we select the top 10, 20, 30, 50, 100, and
150 DERs.
Furthermore, we use eight volumetric radiomics features as illustrated in Table 4. ANOVA
analysis for radiomics in Table 4 shows that feature numbers 1, 3, 4, 7, and 8 are significantly
associated (ANOVA test, p-value < 0.05) with IDH mutations. Our analysis also indicates that
feature number 2 is marginally associated (ANOVA test, p-value = 0.07) with 1p/19q codeletion.
Furthermore, our analysis indicates that feature numbers 3, 4, 6, 7, and 8 are significantly
associated (ANOVA test, p-value < 0.05) with ATRX mutations. Few other studies suggest that
these volumetric imaging features and their ratios are associated with and predictive of several
mutations in Gliomas [143-146].
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Table 4. Radiomics features description and their ANOVA p-value association with IDH
mutations, 1p/19q codeletion, and ATRX mutations.
Feature
Number
1

2

3

4
5
6

7

8

Feature Description
the size of the enhanced tumor to the
necrosis size
the size of the enhanced tumor to the size
of enhanced tumor and necrosis
the size of the enhanced tumor to the
edema size
the size of the enhanced tumor to the
whole tumor size,
the size of the edema to the necrosis size,
the size of the edema to the size of
enhanced tumor and necrosis
the size of the edema to the whole tumor
size
and the size of the necrosis to the whole
tumor size

p-value of

p-value of 1p/19q

p-value of

IDH mutation

codeletion

ATRX mutation

0.0033

0. 393

0.178

0.8630

0.070

0.239

<0.005

0.600

0.002

<0.005

0.707

0.027

0.188

0.996

0.114

0.138

0.789

0.0237

<0.005

0.131

<0.005

<0.005

0.221

<0.005

The 108 LGG cases are randomly split into 80% training and 20% testing sets, and a
balanced distribution of the target molecular alteration is ensured in the training and testing sets in
each molecular classifier. The trained model classifier is developed using the training set. Model
performance prediction is estimated and reported using the testing sets in terms of accuracy,
balanced accuracy, F1 score, sensitivity, specificity, negative predictive value, and positive
predictive value. The training set is utilized to build our radiogenomics-NB classifier as shown in
steps 1-4 in Figure 10. The testing set is used to estimate the performance of the classifier as shown
in steps a and b in Figure 10. Authors in [119, 147-149] repeat training and testing analysis for a
specific number of times to ensure the robustness of the model performance. Consequently, in this
work, we repeat the whole procedure 100 times independently for the 3 molecular alterations and
then report the mean and standard deviation of the classifiers’ performance using the testing sets.
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4.4

RADIOGENOMICS-NB MODELS USING DIFFERENT NUMBERS OF
DIFFERENTIALLY EXPRESSED RNAS

In this section, we investigate the importance of using different numbers of DERs on the
performance of the radiogenomics-NB model. LGG radiogenomics-NB mutation prediction
models are developed based on the top 10, 20, 30, 50, 100, and 150 DERs.
The performance of the radiogenomics-NB IDH model using the top 10 DERs achieves
slightly high performance. However, such improvement is not statistically significant (ANOVA
test, p-value > 0.05) when compared to the performance of the IDH models with the other number
of DERs (Figure 11.a) except for NPV performance when using the top 20 DERs. Using the top
20 DERs in the IDH model achieves significantly (ANOVA test, p-value < 0.05) worse NPV when
compared to the NPV achieved using the top 10 DERs. Radiogenomics-NB IDH model with the
top 10 DERs (red line in Figure 11.a) achieves an overall accuracy (Acc) of 0.92±0.06, sensitivity
(Sens) of 0.94±0.07, specificity (Spec) of 0.83±0.18, positive predictive value (PPV) of 0.96±0.04,
negative predictive value (NPV) of 0.82±0.17, F1 score of 0.95±0.04, and balanced accuracy (B.
Acc) of 0.88±0.09, respectively.
Radiogenomics-NB codeletion models significantly achieve similar performance
(ANOVA test, p-value > 0.05) using the top 10, 20, 30, and 50 DERs as shown in Figure 11.b.
Furthermore, using the top 100 and 150 DERs in the codeletion model achieves worse performance
(ANOVA test, p-value > 0.05) when compared to the performance of using the top 10 DERs. Using
the top 10 DERs, the radiogenomics-NB codeletion model achieves an accuracy of 0.93±0.06, a
balanced accuracy of 0.90±0.10, F1 score of 0.86±0.14, a sensitivity of 0.84±0.19, a specificity of
0.96±0.04, an NPV of 0.95±0.06, and a PPV of 0.90±0.12, respectively.
The radiogenomics-NB ATRX model achieves similar performance (ANOVA test, p-value
> 0.05) using the top 10, 20, and 30 DERs, even though the performance when using the top 10
DERs is slightly better as illustrated in Figure 11.c. Using the top 10 DERs, the ATRX model
achieves an accuracy of 0.85±0.07, a balanced accuracy of 0.85±0.07, an F1 score of 0.82±0.08, a
sensitivity of 0.86±0.13, a specificity of 0.85±0.09, an NPV of 0.91±0.08, and a PPV of 0.80±0.10,
respectively. Table 5 illustrates the confusion matrix of the test performance of the radiogenomicsNB IDH, Codeletion and ATRX models using the top 10 DERs over the 100 repetitions.
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(a)
Figure 11. Performance of the proposed radiogenomics-NB model using a different
number of DERs. a) Radiogenomics-NB IDH, b) Radiogenomics-NB Codeletion, and c)
Radiogenomics-NB ATRX models. The average performance (of the Acc, B. Acc, F1, NPV, PPV,
Sens, and Spec) is computed across 100 testing sets/splits. Y-axis represents the average
performance of the different statistics on the X-axis. Different colors represent the radiogenomicsNB model with different numbers of DERs. The error bar represents one standard deviation.
Asterisk “*” represents a statically significant difference between the performance achieved when
using the top 10 DERs (in red) and using the number of DER where the star is located.
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(b)

(c)
Figure 11 (continued)
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Table 5. Confusion matrix of test performance over 100 repetitions of radiogenomics-NB
IDH, Codeletion, and ATRX models using the top 10 DERs.
Radiogenomics-NB IDH model

Radiogenomics-NB Codeletion

Radiogenomics-NB ATRX

model

model

References

References

References

Predictions

Mutant

WT

Predictions

Codel.

Non-codel

Predictions

Mutant

WT

Mutant

1503

69

Codel.

421

53

Mutant

690

184

WT

97

331

Non-codel

79

1447

WT

110

1016

4.5 COMPARATIVE ANALYSIS

Figure 12 illustrates a graphical performance comparison between our radiogenomics-NB
model with that of four different classifiers in the literature: NBLDA [119], VoomNSC [65, 66],
RF-genomics where we first log-transformed [116] the RNAseq into a normal distribution, and
RF-radiogenomics. Note that the number of DERs that we apply to develop these classifiers is 10
DERs. Moreover, when developing these classifiers, the 108 LGG cases are randomly split into
80% training and 20% testing sets, and balanced distribution is ensured when developing the
different classifiers. The trained model classifier is developed using the training set, and 10-fold
cross-validation is performed to identify the tuning parameters in the different classifiers. Model
performance prediction is estimated and reported using the testing sets. Additionally, to ensure the
robustness of the different classifiers’ performance, we repeat the whole procedure 100 times
independently and every training/testing set is utilized to develop and estimate the performance of
each classifier.
The NBLDA [119] classifier is developed by fitting NB to the top 10 DERs; then the mean
and dispersion parameter are estimated from these DERs. In RF-genomics, the top 10 DERs of the
training sets are first log-transformed into normal distribution and then fed into RF to build the
RF-genomics classifier. In RF-radiogenomics, radiomics (eight volumetric features described
previously in Table 4) are utilized with the log-transformed DERs and then fed into RF to build
the RF-radiogenomics classifier. VoomNSC [65, 121] is developed by first applying the voombased transformation on the 10 DERs and then applying the NSC classifier as illustrated in [65,
121].
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Comparing the performance of our radiogenomics-NB IDH model with that of NBLDA,
RF-genomics, and VoomNSC, the radiogenomics-NB IDH significantly outperforms (ANOVA
test, p-value < 0.05) these methods as shown in Figure 12.a and Table 6. Additionally, our
radiogenomics-NB IDH model significantly outperforms (ANOVA test, p-value < 0.05) the F1
score, balanced accuracy, and PPV performance of the RF-radiogenomics method whereas it
achieves a similar (ANOVA test, p-value > 0.05) accuracy, sensitivity, and specificity. Our
radiogenomics-NB IDH model archives an accuracy of 0.92±0.06, a sensitivity of 0.94±0.07, a
specificity of 0.93±0.18, an F1 score of 0.95±0.04, and a balanced accuracy of 0.88±0.09,
respectively. The RF-radiogenomics-IDH model achieves an accuracy of 0.88±0.17, a sensitivity
of 0.93±0.07, a specificity of 0.78±0.16, an F1 score of 0.92±0.06, and a balanced accuracy of
0.85±0.08, respectively.
Our radiogenomics-NB codeletion model (Figure 12.b and Table 7) performance is similar
to NBLDA, RF-genomics, VoomNSC, and RF-radiogenomics models, except for the specificity
and NPV performance when using RF-genomics and VoomNSC. The specificity and NPV of our
model are significantly higher than those achieved by RF-genomics and VoomNSC. Our
radiogenomics-NB codeletion model achieves an accuracy of 0.93±0.06, a sensitivity of
0.84±0.20, a specificity of 0.96±0.5, an F1 score of 0.86±0.14, and a balanced accuracy of
0.90±0.10, respectively.
The performance of our radiogenomics-NB ATRX model as shown in Figure 12.c and Table
8 outperforms both NBLDA and VoomNSC significantly (ANOVA test, p-value < 0.05).
However, comparing our ATRX model to RF-genomics, our model achieves significantly better
balanced-accuracy, F1 score, NPV, and sensitivity. Additionally, comparing our ATRX model to
RF-radiogenomics, our model achieves significantly (ANOVA test, p-value < 0.05) better
sensitivity but achieves similar accuracy, balanced-accuracy, F1 score, and sensitivity. Our
radiogenomics-NB ATRX model achieves an accuracy of 0.85±0.07, a sensitivity of 0.86±0.13, a
specificity of 0.85±0.09, an F1 score of 0.82±0.08, and a balanced accuracy of 0.85±0.07,
respectively. The RF-radiogenomics ATRX model achieves an accuracy of 0.84±0.08, a sensitivity
of 0.80±0.14, a specificity of 0.86±0.10, an F1 score of 0.80±0.09, and a balanced accuracy of
0.83±0.08, respectively.

60

(a)
Figure 12. Comparison of performance between our radiogenomics-NB model and
different classifiers. The comparison is performed using the a) IDH mutation, b) 1p/19q codeletion,
and c) ATRX mutations dataset. The average performance (of the Acc, B. Acc, F1, NPV, PPV, Sens,
and Spec) is computed across 100 test sets. The error bar represents one standard deviation. RNAseq
that are used in developing all classifiers represent the top 10 DERs in the training sets between
mutated and WT IDH group, codeleted and non-codeleted groups, and mutated and WT ATRX
mutation, respectively. Y-axis represents the average performance of the different statistics on the
X-axis. Different colors represent different classifiers.
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(b)

(c)
Figure 12 (continued)
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Table 6. Probability of significant difference using ANOVA test between the differentially
expressed radiogenomics-NB model and different classifiers using IDH dataset. A statistically
significant difference exists if p-value < 0.05. Values in bold show a significant improvement of our
radiogenomics-NB IDH over the compared one.
IDH
radiogenomics-NB
VS NBLDA
radiogenomics-NB
VS VoomNSC
radiogenomics-NB
VS RF

Balanced

Accuracy

Sensitivity

Specificity

PPV

NPV

F1

0.000

0.010

0

0

0.000

0.000

0

0.000

0.075

0

0

0.000

0.000

0

0.001

0.023

0

0

0138

0.000

0

0.069

0.432

0.061

0

0.084

0.001

0.01

Accuracy

radiogenomics-NB
VS RFradiogenomics

Table 7. Probability of significant difference using ANOVA test between the differentially
expressed radiogenomics-NB model and different models using 1p/19q codeletion dataset. A
statistically significant difference exists if p-value < 0.05. Values in bold show a significant
improvement of our radiogenomics-NB codeletion over the compared one.
CODEL
radiogenomics-NB
VS NBLDA
radiogenomics-NB
VS VoomNSC
radiogenomics-NB
VS RF

Balanced

Accuracy

Sensitivity

Specificity

PPV

NPV

F1

0.232

0.186

0.756

0.514

0.253

0.123

0.181

0.072

0.228

0.001

0.057

0.042

0.742

0.317

0.242

0.390

0.020

0.636

0.027

0.271

0.42

0.671

0.815

0.893

0.825

0.282

0.855

0.792

Accuracy

radiogenomics-NB
VS RFradiogenomics
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Table 8. Probability of significant difference using ANOVA test between the differentially
expressed radiogenomics-NB model and different models using ATRX dataset. A statistically
significant difference exists if p-value < 0.05. Values in bold show a significant improvement of our
radiogenomics-NB ATRX over the compared one.
ATRX
radiogenomics-NB
VS NBLDA
radiogenomics-NB
VS VoomNSC
radiogenomics-NB
VS RF

Balanced

Accuracy

Sensitivity

Specificity

PPV

NPV

F1

0.000

0.269

0.000

0.000

0.677

0.004

0.001

0.003

0.741

0.001

0.002

0.432

0.021

0.012

0.083

0.005

0.540

0.960

0.004

0.026

0.025

0.183

0.003

0.215

0.561

0.003

0.052

0.053

Accuracy

radiogenomics-NB
VS RFradiogenomics

4.6

GENDER-SPECIFIC EFFECT ANALYSIS OF RADIOGENOMICS-NB
In our LGG dataset, IDH mutated patients, unlike IDH WT patients, have significantly

longer survival (65.7 vs 19.9 months, log-rank test p-value = 0.004). The association between IDH
status and overall survival remains significant after stratifying for gender (likelihood ratio test pvalue = 0.015). However, the association between 1p/19q codeletion and ATRX status and overall
survival is not significant. Additionally, the chi-square test shows no significant association (pvalue > 0.05) between gender and IDH status, 1p/19q codeletion, and ATRX status. Table 9 shows
patient IDH status, 1p/19q codeletion, and ATRX status distribution based on gender.
To explore the gender-specific effect in the performance of the radiogenomics-NB, we
build two radiogenomics-NB models based on gender; male-specific radiogenomics-NB and
female-specific radiogenomics-NB. Our analysis indicates that female-specific models outperform
significantly (ANOVA test, p-value < 0.05) male-specific models as illustrated in Figure 13.
Female-specific models achieve an accuracy of 0.93±0.08 and a balanced accuracy of 0.92±0.11
in the radiogenomics-NB IDH, an accuracy of 0.91±0.09 and a balanced accuracy of 0.84±0.17 in
the radiogenomics-NB codeletion, and an accuracy of 0.80±0.11 and a balanced accuracy of
0.80±0.12 in the radiogenomics-NB ATRX, respectively.
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Table 9. Gender-based distribution of IDH status, 1p/19q codeletion, and ATRX status in
the LGG dataset.
IDH status

1p/19q codeletion

ATRX status

Mutant

WT

Codeletion

Non-Codeletion

Mutant

WT

Female

43

14

14

43

24

33

Male

42

9

13

38

19

32

(a)
Figure 13. Gender-based radiogenomics-NB models performance of a) IDH mutations, b)
1p/19q codeletion, and c) ATRX mutations which is computed across 100 testing sets. The error bar
represents one standard deviations. The asterisk * illustrates a significant difference between two
measurements. Y-axis represents the average performance of the different statistics on the X-axis.
Different colors represent the female- and male-specific radiogenomics-NB models.
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(b)

(c)
Figure 13 (continued)
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4.7 DISCUSSION

In this study, we propose a novel radiogenomics-NB model to fuse radiomics (imaging
features) with RNAseq (genes) for glioma grading and prediction. NB distribution is appropriate
for modeling RNAseq discrete read counts data and for preserving the count-based nature of this
data. In the proposed radiogenomics-NB model, log-linear regression modeling is fitted to the
estimated mean of the NB distribution and is linked with radiomics. We introduce this step to fuse
the continuous radiomics data with the RNAseq count-based data without the need to transform
the RNAseq data into a normal distribution.
NB, unlike Poisson distribution, has two parameters; the mean (e.g., the expected value of
the RNAseq read counts data) and dispersion (e.g., a parameter that helps in capturing the
variability of the RNAseq read counts). If the dispersion of NB is zero, the model reduces to
Poisson distribution. In Poisson distribution, the mean is equal to the variance, which makes it
rather restrictive. However, variation is usually observed in the real data of RNAseq counts data
that the Poisson distribution cannot handle properly. On the other hand, NB has an additional
parameter called the “dispersion” that allows the NB distribution of RNAseq counts data to modify
its variance without affecting the mean. Thus, NB serves as a practical approximation to model
RNAseq count data with variability different from its mean.
The mean of the proposed radiogenomics-NB model is estimated as the size factor
multiplied by the total number of reads per RNAseq. Moreover, we utilize EdgeR to estimate the
dispersion of the proposed radiogenomics-NB assuming RNAseq variability is assessed using the
weighted conditional log-likelihood model. In the weighted conditional model, RNAseq counts
data is assumed to have a distinct and individual dispersion for each RNAseq in addition to a
common dispersion. Such an assumption can be more reliable when estimating the dispersion of
real data of RNAseq counts data.
The performance evaluation of the proposed work indicates that linking radiomics (i.e.
tumor volumetric features) to RNAseq improves the performance of IDH and ATRX mutations
prediction. The radiomics features utilized in the proposed radiogenomics-NB model that are
described in Table 1 mainly depend on volumetric features. Our analysis shows that these features
are associated with glioma mutations. This outcome supports previous studies that show the
association between volumetric features and glioma mutations [143-146].
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The efficacy of the proposed radiogenomics-NB model is further investigated using the top
10, 20, 30, 50, 100, and 150 DERs, respectively as illustrated in Figure 12. Our analysis shows
that the smaller the number of DERs (fewer than 30 DERs) utilized in radiogenomics-NB, the
better the radiogenomics-NB model performance. Our analyses indicate that using fewer than 30
DERs in our analysis offers the best performance (statically significant) in the radiogenomics-NB
codeletion and ATRX prediction model. This suggests that using large numbers of DERs (more
than 30) in the proposed radiogenomics-NB would over parametrize the dataset and create model
fitting problems and thus degrade the performance.
Comparing our radiogenomics-NB model to NBLDA, RF-genomics, FR-radiogenomics,
and VoomNSC, our model significantly outperforms NBLDA, RF-genomics, and VoomNSC for
prediction of IDH and ATRX mutations. Our radiogenomics-NB model offers similar performance
as NBLDA, RF-genomics, RF-radiogenomics, and VoomNSC models for prediction of 1p/19q
codeletion. Specifically, for prediction of IDH mutations, while the proposed radiogenomics-NB
model achieves significantly better balanced-accuracy, F1 score, and PPV than RF-radiogenomics,
our model achieves similar accuracy, sensitivity, and specificity. Such results indicate the power
of fusing radiomics and genomics data to develop radiogenomics models for classification and
prediction models. The findings in this work indicate that the radiomics volumetric features may
be vital for the prediction of IDH and ATRX mutations along with the genomics.
Different studies have revealed that gender is a significant factor in identifying cancer
survival, prognosis, and treatment response [150-152]. Hence, improved glioma molecular
mutation prediction may require the development of gender-specific models. In this study, we
explore the gender-specific effect on the radiogenomics-NB models. Our analysis reveals that IDH
mutated patients have significantly longer survival and remain significant after stratifying for
gender, unlike 1p/19q codeletion and ATRX status. Moreover, our analysis indicates that no
association is found between gender and the three mutations (IDH mutations, 1p/19q codeletion,
and ATRX status) using the Chi-square test. This result is in agreement with the findings in [153155]. However, a gender-specific radiogenomics-NB model shows that female-specific
radiogenomics-NB models significantly outperform the male-specific radiogenomics-NB models
for prediction of IDH status, 1p/19q codeletion, and ATRX status, respectively.
There are several limitations to this study. First, the radiogenomics-NB model is proposed
to employ the count-based nature of the RNAseq dataset. We utilize both the sensitivity (the
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probability of test positive when the test is positive) and the specificity (the probability of test
negative when the test is negative) to assess the predictivity of the model. However, using the
measurements of sensitivity and specificity may be not adequate when the normality of the data
cannot be obtained [156]. Second, we assume that all RNAseq counts dataset are independent of
each other in the derivation of the radiogenomics-NB model. This assumption may not be always
realistic, and a gene interaction may affect a certain glioma outcome.
In conclusion, we present a glioma mutations radiogenomics-NB prediction model that
preserves the count nature of RNAseq counts data in the NB model and utilizes radiomics to
develop a complete and a better characterization prediction model of patient data. Our analysis
shows the superiority of utilizing both genomics and radiomics data when compared to only
genomics models. Finally, this study shows the efficacy of volumetric radiomics features in the
radiogenomics-NB model for glioma molecular grading and prediction.
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CHAPTER 5

RADIOMICS-GUIDED PREDICTION OF OVERALL SURVIVAL IN
GLIOBLASTOMA PATIENTS

5.1 CHAPTER OVERVIEW

Radiomics is defined as quantitative imaging features that are extracted from radiographic
images (e.g., MRI). Radiomics have provided insights into personalized medicine and, thus,
provided accurate survival prediction (i.e. risk stratification), tumor detection, subtype
classification, and therapeutic response assessment of oncologic patients [157]. Additionally,
different studies [30, 75, 88, 89, 158] study tumor heterogeneity using different types of imaging
such as MRI. As a result, MRI is suggested as a potential non-invasive imaging biomarker for
gliomas diagnostic, prognostic, and survival prediction. This chapter proposes a fully automated
MRI-based glioblastoma survival prediction framework. The survival prediction framework
includes two representative survival prediction pipelines that combine different feature selection
and regression approaches. The framework is evaluated using two recent widely used benchmark
datasets from Brain Tumor Segmentation (BraTS) global challenges in 2017 and 2018.

5.2 GLIOBLASTOMA SURVIVAL PERDITION USING RADIOMICS

In this section, two different survival prediction models are proposed for survival
prediction. The first model is a tree-based method for overall-survival regression prediction using
a three-step feature selection and Random forest (RF) regression model (Figure 14.a). The second
survival prediction model (Figure 14.b) includes a prediction of survival risk classification (short,
medium, and long-term survival). Subsequently, an overall survival regression is performed based
on the survival risk class label. Both classification and regression models are trained on
quantitative- radiomics features obtained from the segmented tumor. The recursive feature
selection method is used to select the features that are used in the classification model. Finally,
Cox regression is used as a feature selection method in the overall survival regression model. Three
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overall regression models are trained: long-regression model, mid-regression model, and short
regression model.

5.3 METHODOLOGY

5.3.1

MATERIALS

This study uses BraTS18 training, validation, and testing dataset [123-125, 159], and
BraTS17 training, validation, and testing datasets for patient survival prediction analysis. Both
BraTS17 and BraTS18 datasets contain a total of 163 Glioblastoma (high-grade glioma (HGG))
cases for training, with overall survival, defined in days, and the age of the patient at diagnosis,
defined in years. The training dataset provides 4 modalities (T1, post-contrast T1-weighted
(T1Gd), T2-weighted (T2), T2 Fluid Attenuated Inversion Recovery (FLAIR)) along with the
ground truth segmentation of multiple abnormal tissues (enhanced (EN), edema (ED), necrosis
and non-enhanced (NCR/NET)) in the tumor. Overall survival risk is classified into three survival
groups: long (greater than 15 months), medium (between 10 to 15 months), and short (less than 10
months).
In addition, for validation purposes, we use the validation datasets of BraTS17 and
BraTS18. BraTS17 validation dataset consists of thirty-three cases while that for BraTS18 consists
of twenty-eight cases for overall survival prediction purposes. BraTS17 testing dataset consists of
ninety-five cases while that for BraTS18 offers seventy-seven cases for testing the overall survival
prediction performance. A total of 135 pre-operative GBM BraTS18 training patients are provided
by The Cancer Imaging Archive (http://www.cancerimagingarchive.net/). The overall survival
(OS), age at diagnostic (median age, 59 years; range, 17 – 84 years), and other clinical data,
molecular mutations, and genomics data are downloaded from the Genomic Data Commons Data
Portal (https://portal.gdc.cancer.gov/).
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(a)

(b)
Figure 14. Glioblastoma Survival Prediction Model Outline using Radiomics. a) The first
survival prediction model (SP1) pipeline using RF regression classifier, and b) the second survival
prediction model (SP2) pipeline using XGBoost.

72
5.3.2

FEATURE EXTRACTION

Feature extraction is the first step in the overall survival prediction task. Different
quantitative imaging features (of around 31 thousand) are extracted from the different types of
segmented abnormal tissues (edema, enhanced tumor, and tumor core). These features include
texture, volumetric and area-related features, histogram-graph features, and Euler characteristics
(vertices, edges, and faces). The heterogeneity in Glioblastoma may be quantified using texture
and histogram-graph features while the shape of the tumor may be effectively captured using
volumetric and Euler characteristic features [74, 76, 160].

TEXTURE FEATURES
A detailed breakdown of the extracted features is as follows: a total of 1107 texture features
[127] are computed from the raw MRI sequences and different texture representation of the tumor
volume. The texture representations of the raw MRI are 1) Texton filters [93] 2) texture-fractal
characterization using piecewise-triangular prism surface area (PTPSA) [96] modeling, 3) fractal
characterization of multi-fractional Brownian motion (mBm) [97] modeling, 4) and the Holder
Exponent [129] modeling. The extracted texture imaging features are described by 1) the
histogram, 2) the co-occurrence matrix, 3) the neighborhood gray-tone difference matrix, and 4)
the Size Zone Matrix. Histogram features describe the first-order statistical properties of the image
[161]. The features (that are described by the co-occurrence matrix) measure the texture of the
image using Haralick statistical features [162]. The features (that are described by the
neighborhood gray-tone difference matrix) measure a grayscale difference between pixels with
certain grayscale and their neighboring pixels [133]. The features (that are described by Size Zone
Matrix) are estimated using run-length techniques [163].
Furthermore, six histogram-based statistics (mean, variance, skewness, kurtosis, energy,
and entropy) features are extracted from the edema, enhanced tumor and necrosis tissues.

VOLUMETRIC AND AREA-RELATED FEATURES
Thirteen volume-related features are considered: the volume of the whole tumor, the
volume of the whole tumor with respect to the brain, the volume of sub-regions (edema, enhanced
tumor, and necrosis) divided by the whole tumor, the volume of sub-regions (edema, enhanced
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tumor, and necrosis) divided by the brain, the volumes of the enhanced tumor and necrosis divided
by the edema, the summation of the volume of the edema and enhanced tumor, the volume of the
edema divided by the summation of the volume of enhanced tumor and necrosis, and the volume
of the necrosis divided by the summation of the volume of the edema and enhanced tumor. The
tumor locations and the spread of the tumor in the brain are computed. Another nine area-related
properties (area, centroid, perimeter, major axis length, minor axis length, eccentricity, orientation,
solidity, and extent) are computed from three viewpoints (x, y, and z-axes) of the whole tumor.

HISTOGRAM-GRAPH FEATURES
A total of 832 features extracted from the histogram graph of the different modalities of
the whole tumor, edema, enhancing, and necrosis regions. These features represent the frequency
at different intensity bins (of 11,15, and 23) and the bins of the max frequency.

EULER CHARACTERISTICS
Finally, we compute the Euler characteristic [164] of the whole tumor, edema, enhancing,
and necrosis, for each slice. The Euler characteristic features are computed on the tumor curve, at
100 points, and at 72 different angles. Then, the Euler characteristic features are integrated over
all slices. As a result, each patient is represented by 4 (whole tumor, edema, enhancing, and
necrosis) Euler characteristic feature vectors. Each vector has a size of 7200 (100 points × 72
angles).

5.3.3

SURVIVAL PREDICTION MODELS

Two different survival prediction models are proposed for survival prediction. The first
model is a tree-based method for overall-survival regression prediction using the Random Forest
(RF) regression model. We have employed RF due to its efficiency, robustness, and flexibility in
utilization for both multi-class classification and regression tasks [165]. Additionally, RF does not
require extensive hyper-parameter tuning and is resilient to overfitting. These traits make RF
preferable over more common models such as artificial neural networks especially when the
training data is limited. The complete pipeline for the survival regression using RF is illustrated in
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Figure 14.a. This model uses significant, predictive, and important features selected from
the above-mentioned texture, histogram-graph, and volumetric and area-related features. A threestep feature selection method is utilized as follows. Univariate Cox regression is fitted on every
extracted feature, and features with p-value < 0.05 are considered significant. Second, univariate
Cox regression is fitted on the quantitative copy of the significant features. The quantitative copy
is obtained by thresholding the significant feature around its median value. The last step is
performed to ensure that each significant feature is also able to split the data set into long vs. short
survival. Then, recursive feature selection is applied to the 240 features. Finally, the RF regression
model with tenfold cross-validation is used to evaluate the model at each iteration.
The model in Figure 14a is used as a baseline to obtain a second more comprehensive
survival prediction pipeline as shown in Figure 14.b. We incorporate additional features such as
Euler characteristics. The features for the updated model are then selected using the recursive
feature selection method as follows. First, we perform recursive feature selection (RFS1) on the
Euler features alone. Next, another recursive feature selection (RFS2) on the remaining features
(texture, volumetric, histogram-graph based) is performed. In addition, the overall-survival
regression model uses Cox regression to select significant features with a p-value < 0.05.
Moreover, we introduce a state-of-the-art Extreme Gradient Boosting (XGBoost) [131] based
regression technique for stepwise survival risk classification and overall-survival regression
prediction using the selected features. The XGBoost based regression model is applied to each of
the three groups (short, medium, and long) to obtain survival duration in the number of days,
respectively. One of the major advantages of XGBoost is utilization of L1 and L2 regularization.
L1 regularization handles sparsity, whereas L2 regularization reduces overfitting [131]. It is worth
noting that we have not utilized any neural network models for the survival prediction because the
sample size in this study is not large enough to ensure good training in a neural network setting.

5.4 OVERALL SURVIVAL PREDICTION FRAMEWORK EVALUATION

The proposed framework consists of two distinct radiomics based automated survival
prediction pipelines. Accordingly, we obtain extensive performance evaluation using two
pipelines: the first one comprises three-step feature selection and the RF-based survival prediction
method (henceforth referred to as SP1), while the second consists of XGBoost based survival
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prediction algorithm (henceforth referred to as SP2). We first participated in the BraTS 2017
challenge, and the specific combination of machine learning methods with RF survival prediction
model (known as SP1) offered the best overall performance in this challenge. We subsequently
participated in the BraTS 2018 challenge, and the augmented model (known as SP2) offered the
best performance using the validation dataset.

Table 10. Performance of SP1, SP2, and modified-SP2 methods with BratS17 and
BraTS18 datasets. The evaluation of validation is performed using the online evaluation platform
of CBICA IPP (https://ipp.cbica.upenn.edu).
Survival Prediction Performance
Model/Dataset

Accuracy

Mean Square Error

SP1/ BraTS17 training

0.67

78,929

SP1/ BraTS17 validation

0.667

209,908

SP1/ BraTS17 test

0.579

245,780

SP2/ BraTS18 training

0.73

91,585

SP2/ BraTS18 validation

0.679

153,466

SP2/ BraTS18 test

0.519

367,240

RF-SP1/ BraTS18 validation

0.464

170,737

XGBoost-SP2/ BraTS17 validation

0.636

218,097

Modified-SP2/ BraTS18 training

0.718

99,358

Modified-SP2/ BraTS18 validation

0.679

127,697

For SP1 the survival prediction features are the age and 40 texture and volumetric features.
The distribution of the 40 features is as follows: 12 features extracted from Texton of the tumor, 9
features extracted from the Holder exponent representations of the tumor, 6 features represent the
histogram of the abnormal tissues, 5 from the raw MR modality of the tumor and sub-regions, 4
describe the volume of the tumor and the sub-regions, and 4 features are extracted from the tumor
area and major axis length.
In comparison, as discussed above and shown in Figure 14.b for SP2, all relevant features
are extracted from the ground truth cases available with the BraTS18 training dataset. The
subsequent recursive feature selection for Euler features (28 thousand) alone generates 39 features.
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The distribution of the 39 Euler features includes 16 features computed around the contour of ET,
16 features computed around that of WT, and 7 features computed around that of edema,
respectively. The application of recursive feature selection on the remaining features produces an
additional 23 texture features, 4 histogram graph features, and 8 area features of the edema, ET,
and WT, respectively. The XGBoost with leave-one-out cross-validation (LOOCV) is employed
on the selected 74 features and the age to predict three corresponding survival classes (short,
medium, long). This yields a classification accuracy of 0.73 (95% confidence intervals [CI]: 0.6550.797) for the BraTS18 training dataset.

Table 11. Confusion matrix of SP1, SP2, and modified-SP2, and some statistics derived
from the confusion matrix based on each survival label in the training model.
SP1 2017

SP2 2018

Modified-SP2 2018

Reference

Reference

Reference

Predictions

Long

Med

Low

Long

Med

Low

Long

Med

Low

Long

32

7

10

43

13

4

44

11

4

Med

24

34

12

5

18

3

7

18

6

Low

0

1

43

8

11

58

5

13

55

Total number of cases

56

42

65

56

42

65

56

42

65

Statistics

SP1 2017

SP2 2018

Modified-SP2 2018

Sensitivity

0.571

0.810

0.662

0.768

0.429

0.892

0.786

0.429

0.846

Specificity

0.841

0.702

0.990

0.841

0.934

0.806

0.860

0.886

0.816

Balanced Accuracy (Sen. + Spec.)/2

0.706

0.756

0.826

0.804

0.681

0.849

0.823

0.657

0.831

Positive Prediction Value (PPV)

0.653

0.486

0.977

0.717

0.692

0.753

0.745

0.581

0.753

Negative Prediction Value (NPV)

0.789

0.914

0.815

0.874

0.825

0.919

0.885

0.817

0.889

First, we establish the performance of both SP1 and SP2 methods using the BraTS17 and
BraTS18 training and validation datasets. The training dataset performance is obtained through
leave-one-out cross-validation analysis. The performance evaluation of methods using BraTS
validation datasets is restricted to the online evaluation platform of the organizer of the BraTS
challenge (CBICA IPP at https://ipp.cbica.upenn.edu) and must be performed during a specific

77
time period during the challenge. Note that the second pipeline (SP2) is developed after the BraTS
2017 challenge is concluded; hence, the 2017 validation portal is no longer available for
evaluation. However, a fair comparison between the pipelines can still be obtained through the
training data evaluations and the validation evaluations of respective challenge years. The results
are summarized in Table 10 and Table 11.

Table 12. Performance of LOOCV of the three regression models in SP2 and modifiedSP2 in the XGBoost overall survival model.
SP2
Root
Regression model

Mean

Mean

Square

Absolute

Error

Error

294.177

86,540

217.714

35.629

1,269

61.449

3,776

Mean
Square
Error

Long-regression
model
Mediumregression model
Short-regression
model

Modified-SP2
Root

Mean

Mean

Square

Absolute

Error

Error

302.069

91,246

209.253

28.190

40.702

1,657

34.971

50.402

80.340

6,455

65.094

Mean
Square
Error

The results in Table 10 for training and validation illustrate that the SP2 model offers better
performance in accuracy over that of the SP1 model. The SP2 model also obtains improvement
over SP1 in validation MSE. Note, the SP1 model has been ranked the first in the BraTS 2017
challenge for survival prediction category among seventeen teams globally. The overall high MSE
for survival prediction is particularly due to the wide range within the long-term survival category
resulting in large prediction errors. Further note that the MSE of SP2 for BraTS18 training is the
sum of the three MSE (Table 12) values obtained for the short-, medium-, and long-regression
models shown in Table 12. Finally, the test results for both SP1 for BraTS17 and SP2 for BraTS18
in Table 10 show that SP1 performed better in patient-survival prediction than that for SP2. This
performance difference for SP1 and SP2 models is further analyzed below.
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5.4.1

COMPARATIVE EVALUATION OF SURVIVAL PREDICTION

PERFORMANCE WITH SP1 AND SP2

Table 11 shows the confusion matrix of both SP1 and SP2 and relevant statistics for each
class in the classification training model for survival risk prediction. The sensitivity and balanced
accuracy of the medium survival group in SP2 is the lowest when compared to the other two
survival groups. The top four important features as ranked by XGBoost are tumor extent in the zaxis, the width of the enhanced tumor computed from x-axis point of view, and contour around the
edema contour and enhanced tumor. The mean value of each of the four features is able to
significantly (p-value < 0.05) stratify the 163 cases into two risk groups (low-risk and high-risk)
as illustrated in Figure 15.
Our analysis of Figure 15 reveals that thresholding the value of features around the mean
can stratify the 163 cases significantly (log-rank test, p-value < 0.05) into two survival groups. The
features and the median survival of each group are:
•

the tumor extent from z-axis viewpoint stratifies the 163 cases into two groups with a median
survival of 394 days vs 318 days,

•

the enhanced tumor width from x-axis viewpoint stratifies the 163 cases into two groups with
a median survival of 437 days vs 268 days,

•

the contour around the edema stratifies the 163 cases into two groups with a median survival
of 387 days vs 330 days,

•

and contour around the enhanced tumor stratifies the 163 cases into two groups with a median
survival of 421 days vs 278 days.
The second step in the survival prediction is to obtain individual regression training models

corresponding to the short, medium, and long survival classes. These short-, medium-, and longregression models use features selected distinctly for each survival class using Cox regression
(with p-value < 0.05). The number of significant features selected for the short-, medium-, and
long-regression models is 83, 51, and 148, respectively. Table 12 illustrates the performance of
LOOCV with XGBoost for the selected features using specified survival risk cases in BraTS18
training cases.
Note that the wide range of the overall survival of the long-survival group (greater than 15
months) may cause the RMSE of the long-regression model to have the highest RMSE (Table 12).
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This also may cause a high mean square error when using the validation dataset (Table 10). The
range of the overall survival of the short-survival group is 10 months, whereas the mediumsurvival group is 5 months.

5.4.2

MODIFIED-SP2

In order to reduce the high dimensionality of the features in SP2 classification and
regression steps, we modify SP2 in Figure 14.b as follows: 1) calculate and rank the feature
importance for each classification and regression model; 2) select features that have relative scaled
importance greater than 50%; 3) train the modified selected features in a new classification and
regression training models utilizing XGBoost. The resulting 30 significant features are applied in
the classification step of the modified-SP2. The distribution of these features is as follows: 13
features represent Euler characteristics, 7 features represent volumetric and area-related properties,
4 histogram-graph based features, 5 texture features, and one feature with age information.
The number of significant features used in the short-, medium-, and long-regression models
of the modified-SP2 is 11, 9, and 11, respectively. The distribution of the features in the modified
short-regression model is as follows: 2 volumetric and area-related features, 1 histogram-graph
based features, 7 texture features, and one feature with age information. The features employed in
the modified med-regression model are 5 volumetric and area-related features, 3 texture features,
and Age. The features of the modified long-regression model are 2 volumetric and area-related
features, 8 texture features, and one feature with age information.
The modified-SP2 achieves cross-validated accuracy of 0.718 as illustrated in Table 10.
Table 11 illustrates the statistics of its confusion matrix in the classification training model. Table
12 illustrates the performance of the modified regression training models. Additionally, the
modified-SP2 is validated using the BraTS18 validation set, and its performance is illustrated in
Table 10. Note that the different performances of SP2 and modified-SP2 are almost similar when
using the BraTS18 training and validation dataset statistics of each class in SP2 and the modifiedSP2 are almost similar. This can be explained by the fact that XGBoost provides L1 and L2
regularization. Additionally, the modified-SP2 is validated using the BraTS18 validation set, and
its performance is illustrated in Table 10.
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(a)

(b)
Figure 15. Kaplan Meier of the top four important features used in SP2. The features are
divided around its mean value to stratify the 163 subjects into two groups: high risk group (red line),
and low risk group (blue line). The features are (a) tumor extent; (b) the enhanced tumor width; (c)
contour around the edema; and (d) contour around the enhanced tumor. The shaded area indicates
the 95% confidence interval. The time is measured in days.
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(c)

(d)
Figure 15. (continued)
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5.5 CRITICAL ANALYSIS OF FEATURES UTILIZED IN THE SURVIVAL
PREDICTION PIPELINES

This section provides a critical analysis of the features and their effects on survival
prediction performance. As mentioned in the previous sections, the features that are derived from
different abnormal tissue types in the tumor of the segmented tumor region significantly contribute
to the survival prediction performance. Accordingly, we visualize the features extracted from
different abnormal tissue types of the segmented tumor. The visualization is performed using one
of the most widely-used high-dimensional data visualization techniques known as t-Distributed
Stochastic Neighbor Embedding [132] (t-SNE). First, t-SNE is used to explore the features
obtained from different abnormal tissue types from the segmented tumor region and analyze the
effects of these features on the performance of the survival prediction task using the BraTS 2017
and BraTS 2018 dataset.
For the SP1 pipeline, we extract a total of 40 features from the sub-tissue types of the
segmented tumor region. The features extracted in SP1 are as follows: 36 features for the whole
tumor, 2 features for the enhanced tumor, and 2 features for edema. We visualize the feature
clusters for patient survival categories: long, medium, and short term. In this case, we consider all
40 features obtained from the 163 BraTS17 training data as mentioned above and explore the
grouping against the tumor risk labels using the t-SNE technique. Figure 16 shows the visualization
of the corresponding features for long, medium, and short risk labels. Note that all the visualization
outcomes shown are obtained after extensive hyper-parameter tuning of t-SNE to produce the best
possible results. Figure 16 demonstrates that though there is some separation of corresponding
features between the long and short categories, the medium category is mixed with both long and
short categories. This suggests that it is still difficult to visualize a clear separation of extracted
features for the survival prediction task with the available patient dataset for this study. The
corresponding survival prediction performance of the SP1 pipeline using the testing dataset is as
shown in Table 10 and Table 12. As mentioned above, though the SP1 pipeline was ranked first
place in the BraTS 2017 challenge, the feature distribution in Figure 16 suggests an inherent
challenge in extracting representative features for the survival prediction task.
Next, we explore the features and their effects on the performance of our SP2 pipeline
using the BraST18 dataset. We extract a total of 74 features and the age for the SP2 pipeline. The
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features extracted in SP2 are as follows: 43 features for the whole tumor, 22 features for the
enhanced tumor, 8 features for edema, and 1 feature for necrosis. Figure 17 shows the visualization
of the 74 features in terms of long, medium, and short risk labels using the 163 sample BraTS18
training data. Our analysis suggests that the tSNE technique again fails to group the features in
long, medium, and short categories. Though there is some separation between the corresponding
features for long and short categories, the features for the medium category mix with both short
and long categories for multiple subjects, quite similar to the visualization of SP1. This poor
separation may still be due to the lack of sufficient representative strength of the features for
categorizing different risk labels. Consequently, Table 10 shows that our proposed SP2 pipeline
achieves 0.73, 0.679, and 0.519 accuracies on the BraTS18 training, validation, and testing data.
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(a)

(b)
Figure 16. SP1 feature visualization. (a) The 3D; and (b) the 2D plot of t-Distributed
Stochastic Neighbor Embedding (t-SNE) of the selected features of SP1 clustered based on the long,
medium, and short risk labels using BraTS17 training dataset.
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(a)

(b)
Figure 17. SP2 feature visualization. (a) The 3D plot of the t-Distributed Stochastic
Neighbor Embedding (t-SNE) of the selected features of SP2 clustered based on the long, medium,
and short risk labels using BraTS18 training dataset. (b) The 2D plot of the same training dataset.

Additionally, we validate our RF survival prediction in SP1 (RF-SP1) using the BraTS18
validation set. We also validate XGBoost survival prediction in SP2 (XGBoost-SP2) using the
BraTS17 validation dataset. The results are summarized in Table 1. Using the BraTS17 validation
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dataset, the RF-SP1 model achieves 67.7% accuracy, whereas the XGBoost-SP2 model achieves
63.6%. Using the BraTS18 validation dataset, the RF-SP1 model achieves 46.4% accuracy,
whereas the XGBoost-SP2 model achieves 67.9% accuracy. These results indicate that the
XGBoost-SP2 combination performs considerably better than that of the RF-SP1 with the
BraTS18 dataset and reasonably well with the BraTS17 dataset, respectively. Note that the ground
truth of the BraTS17 and BraTS18 validation dataset is not provided. As a result, we have
segmented the BraTS17 and BraTS18 validation dataset using the semantic label fusion model of
CNN and RF [95] and the semantic label fusion of U-Net and FCN [92], respectively.

5.6 COMPARISON OF SURVIVAL PREDICTION WITH STATE-OF-THE-ART
WORKS

Comparison of the proposed survival prediction pipelines SP1 and SP2 with some of the
state-of-the-art methods in the literature is discussed next. Table 13 summarizes the performances
of these state-of-the-art models and presents a comparison with our proposed framework (SP2).
Reference [166] proposes using histogram features extracted from denoised MR images (by using
2 levels of the Daubechies wavelet transform) in a support vector machine to predict overall
survival. Their method achieves a 10-fold cross-validation accuracy of 0.667 using the BraTS17
training dataset. Reference [167] extracts volumetric, spatial, morphological, and tractography
features from MR images. Feature normalization and selection is performed, and the selected
features are trained in a support vector machine model. Their proposed model achieves an accuracy
of 0.7 using the BraTS18 training dataset and an accuracy of 0.5 using the BraTS18 validation
dataset. Reference [168] utilizes volumetric features along with Random Forest to predict overall
survival. Their method achieves five-fold cross-validation accuracy of 0.638 using the BraTS17
training dataset. The results demonstrate that our proposed framework achieves higher accuracy
in overall survival prediction compared to the current-state-of-the-art models applied to the same
datasets. Note, unlike our proposed SP1 and SP2 pipelines, the reported performance for all these
other methods in Table 13 are obtained by the authors themselves.
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Table 13. Comparison of our proposed survival prediction pipeline with state-of-the-art
methods in literature.
Reference

Chato et al.[166]

Algorithm

Validation
method

histogram features

10-fold cross

along with SVM

validation

Performance

BraTS17
accuracy of 0.667

Kao et al.[167]

5-fold cross-

tractography features along

validation

BraTS18
Accuracy of 0.7

volumetric features along with

5-fold cross

[168]

Random Forest

validation

XGBOOST overall
survival prediction
model (SP2)

Texture, Volumetric,

LOOCV

histogram-graph, and Euler
features
Along with XGBoost

Validation
dataset

training
dataset

with SVM
Soltaninejad et al.

training
dataset

volumetric, spatial,
morphological, and

Dataset

BraTS17
Accuracy of 0.638

training
dataset

Accuracy of 0.73

BraTS18

and MSE of

training

91585.51

dataset

Accuracy of 0.679

BraTS18

and MSE of

validation

153466.3

dataset

5.7 DISCUSSION

This work proposes a novel framework for fully automated radiomics-based Glioblastoma
survival prediction. The overall framework is designed as a two-step process where feature
selection is carried out in the first step, and then the survival prediction is carried out in the second
step. The framework includes two survival prediction algorithms SP1 and SP2, represented using
feature types, feature selection, regression, and classification methods.
The primary survival pipeline (SP1) combines three-step feature selection and the RFbased survival prediction algorithm to obtain the final output. The second pipeline (SP2) consists
of XGBoost based survival prediction algorithm. As shown in Table 10 and Table 13 the pipelines
used in both SP2 and SP1 offer a comparative survival prediction performance. The functionality
of SP2 is further enhanced by using additional features extracted from the sub-tissues (edema,
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enhanced tumor, and necrosis) and a two-step classification and regression method. Different
studies [158, 169-171] correlate between survival prediction in glioblastoma and different subtissues. SP2 shows improvements over our primary survival prediction model (SP1) [91] with
LOOCV accuracy increase to 0.73 from 0.67 for training datasets, whereas the modified-SP2
achieves cross-validation accuracy of 0.718 using the training dataset.
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CHAPTER 6

SUMMARY AND FUTURE WORK

6
Computational modeling for non-invasive methods that analyze clinical outcomes for
patients has emerged as a vital and promising body of research. For example, these non-invasive
methods are important in tumor progression analysis and classification of molecular mutations in
diffuse gliomas prior to invasive tissue sampling. Radiomics may be used to quantify tumor
heterogeneity that varies between patients and even within a patient. Consequently, radiomics has
an essential role in current radiology practice such as disease diagnosis, monitoring, and treatment
planning. This dissertation proposes computational models for non-invasive survival prediction,
molecular classification, and grading prediction based on radiomics and clinical data for diffuse
glioma patients. Furthermore, statistical models are proposed for molecular mutation classification
and grading based on genomics count-based data and radiomics utilizing the negative binomial
regression. To evaluate the efficacy of the proposed methods discussed in this dissertation, we
cross-validate, test, and compare the performance with state-of-the-art methods.
In Chapter 3, we investigate the efficacy of our novel fractal and multi-resolution fractal
radiomics features on the performance of the non-invasive prediction of molecular mutation in
diffuse LGG. We address diffuse LGG molecular grading and classification using radiomics
features extracted from multimodality MRI of the segmented tumor volume. The extracted
radiomics features describe the multi-resolution fractal modeling, texture features, volumetric, and
area-based characteristics. In the LGG molecular grading and classification model, different
molecular (IDH, 1p/19q codeletion, ATRX, and TERT), and MGMT methylation prediction models
are introduced. Our analysis of the MGMT classification reveals that the less aggressive
methylated MGMT status associates significantly with higher values of the histogram entropy (i.e.,
uncertainty) of tumor mBm and carries HR of 0.579 per standard deviation (likelihood ratio test
p-value = 0.035). The study further shows that the highly aggressive MGMT un-methylated LGG
associates with the higher values of the size ratio between enhanced tumor and necrosis. The
histogram entropy of tumor mBm and the size ratio between enhanced tumor and necrosis are
among the most predictive features of MGMT methylation status. Our IDH mutation classification
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indicates that the tumor correlation associates significantly with mutated IDH and the complexity
of HE of the enhanced tumor associates significantly with WT IDH status. Furthermore, our
analysis reveals that the size ratio between the enhanced tumor and necrosis is a significant
predictor feature of the IDH status which is also a significant predictor of MGMT status.
Furthermore, our analysis of the 1p/19q codeletion classification model indicates that the location
of the upper-left necrosis bounding box and horizontal coordinate of the necrosis centroid are
among the most predictive features and that high values of histogram entropy of tumor mBm
associate significantly with the existence of 1p/19q codeletion. Our analysis of the ATRX status
classification model reveals that the tumor information-measure of correlation and the mean of the
tumor histogram are the most frequently selected features and that the higher values of
information-measure of correlation are associated significantly with WT ATRX. Moreover, the
TERT classification model analysis shows that tumor information-measure of correlation and the
upper-left coordinate in the edema bounding box are the most frequently selected features. Higher
values of these two features are significantly associated with mutated TERT status. In addition, our
analysis suggests that the higher values of the inverse difference moment of HE associates
significantly with WT TERT and offers HR = 0.612 per standard deviation (likelihood ratio test,
p-value = 0.03). High values of the inverse difference moment of an HE tumor predict the less
aggressive WT TERT. Finally, our molecular mutations classification models reveal that fractal
features significantly affect MGMT, IDH, 1p/19q co-deletion, and ATRX prediction models.
Features analysis and the performance of the molecular mutations classification models in Table
2 confirm our hypothesis by showing the importance of the fractal features in diffuse LGG
molecular mutations prediction.
A thorough study utilizing the genomics count-based data along with radiomics in a
negative binomial regression model (i.e., radiogenomics-NB) is discussed in Chapter 4. We
employ both RNAseq counts data and radiomics features to perform molecular mutations
classification and prediction in diffuse LGG. The NB distribution is proposed to model RNAseq
counts data, and the log-linear regression model is utilized to model the relationship between the
estimated model mean and radiomics. The proposed radiogenomics-NB model preserves the
count-based nature of RNAseq data, fuse radiomics and RNAseq counts data, and develop a
complete radiogenomics-NB model with better characterization of patient data. This study
investigates three radiogenomics-NB molecular mutation models; IDH mutation, 1p/19q
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codeletion, and ATRX mutation. We investigate the efficacy of using the top different number of
DERs. Our analysis reveals the best performance of the radiogenomics-NB models is achieved
using 10 DERs. Moreover, we investigate the gender-specific effect on the radiogenomics-NB
models. Our analysis reveals that female-specific radiogenomics-NB models significantly
outperform the male-specific radiogenomics-NB models for prediction of IDH status, 1p/19q
codeletion, and ATRX status, respectively. Additionally, we compare our radiogenomics-NB
model to NBLDA, RF-genomics, FR-radiogenomics, and VoomNSC. Our model significantly
outperforms NBLDA, RF-genomics, and VoomNSC for prediction of IDH and ATRX mutations,
which indicates the power of fusing radiomics into genomics data to develop classification and
prediction models.
Furthermore, in Chapter 5, a fully automated radiomics-based overall survival prediction
framework for glioblastoma patients is discussed. The overall survival prediction framework
comprises two different pipelines that combine different feature selection and regression
approaches. The survival prediction framework is assessed using two recent widely used
benchmark datasets: BraTS17 and BraTS18. The framework predicts the overall survival in days
and classifies the overall survival risk into three survival groups: long (greater than 15 months),
medium (between 10 to 15 months), and short (less than 10 months). Our analysis using the t-SNE
tool reveals that selected features are able to separate between the long- and short-term survival
categories, while the medium-term survival category is mixed with both long and short categories.
This poor separation of the medium category may still be due to the lack of the sufficient
representative strength of the radiomics for categorizing different risk labels The performances of
the overall survival pipelines (SP1 and SP2) demonstrate that our proposed framework achieves
higher accuracy in overall survival prediction compared to the current-state-of-the-art models
applied to the same datasets. The proposed pipeline SP1 achieves the best performance in the
BraTS 2017 in the survival prediction task.

6.1 FUTURE WORK

The analysis of glioma survival prediction and molecular mutations classification and
predictions that are discussed in this dissertation show competitive performance when compared
with the state-of-the-art methods. However, there are a few limitations to this work. Future studies
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are necessary to address these limitations and enhance the performance of the glioma outcome
analysis and prediction models proposed in this work. Future studies are necessary for the following
areas. In Chapter 3, the performances of the proposed LGG molecular mutation classification and
prediction model show promise when compared to different methods and models in the literature.
In the study, we target radiomics features in LGG patients. These molecular mutations are not
carried by LGG patients only. Therefore, in the future, a full-scale study of a more diverse dataset
of glioma patients (not only LGG patients) may reflect higher reliability of the performance of the
proposed molecular mutations prediction model. Additionally, utilizing important clinical data
(e.g., age at diagnosis, gender, ethnicity, tumor morphology, and Karnofsky Status) along with the
existing radiomics may offer more powerful non-invasive molecular mutation classifying models.
In Chapter 4, we propose volumetric radiomics in the radiogenomics-NB model. However,
different mutations may be better predicted in the radiogenomics-NB model using different clinical
information and/or radiomics. In the future, a superior framework/mechanism is needed to
investigate a specific radiomics and associate them with the different mutations and their RNAseq
read counts data through the NB model. Moreover, in the derivation of the radiogenomics-NB
model, we assume that all RNAseq are independent of each other. This assumption may not always
be realistic, and gene interaction may affect a certain glioma outcome. Therefore, it is necessary to
consider the gene interaction effect to extend the radiogenomics-NB model.
Even though in Chapter 5, the SP1 ranked first in the BraTS 2017 challenge and SP2
achieved a competitive performance, there are a few limitations of the proposed models. First, the
total number of cases for the survival training dataset is 163, and both BraTS 2017 and BraTS
2018 required that the data must be divided into three separate survival groups. Consequently, the
number of training cases are divided among three groups as follows: 65 cases for short, 42 cases
for medium and 56 cases for the long survival group, respectively. Therefore, future work includes
a larger dataset for training each regression model to improve model performance. Second, this
study may benefit from additional clinical data such as gender, race, and Karnofsky Status to
strengthen the reliability of the different survival regression and classification models. Finally, the
overall survival risk classification performance of the state-of-the-art methods in the literature,
including the pipelines proposed in this work, may be improved further. The visualization of
survival features suggests the difficulty in separating the high dimensional data into the three
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distinctive risk classes. In addition, there is a need for further research in fusing clinical data with
radiomics and novel feature engineering for survival prediction.
Finally, the work in this dissertation mainly presents multiple models for glioma outcome
survival analysis and prediction, and molecular mutations classification. However, the therapeutic
outcome prediction requires a careful investigation of the imaging changes before and after the
therapeutic session in a proper computational machine learning model. Furthermore, to develop a
full and robust clinical outcome framework, the therapeutic outcome should be assessed and
predicted. Such a study requires an understanding of the therapeutic modality and the relevant
clinical data (e.g. age, gender, the severity of the tumor), radiomics (e.g., tumor volume, tumor
location, the proportion of necrosis), and genomics (e.g., existed mutations), and other omics data
predictors of the treatment outcome.
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